Document:

EX-10.2

 Exhibit 10.2 

EXECUTION COPY 
 CONFIDENTIAL 

SUPPLEMENTAL STOCK ISSUANCE AGREEMENT 

THIS SUPPLEMENTAL STOCK ISSUANCE AGREEMENT
(“Agreement”) is made and entered into as of January 10, 2014 (the “Effective Date”), by and among Fibrocell Science, Inc., a Delaware corporation (the “Company”) and Intrexon Corporation, a
Virginia corporation (“Intrexon”). 
 A. Concurrently with the execution of this Agreement, the Company is entering
into a Second Amendment (the “Amendment”) to that certain Exclusive Channel Collaboration Agreement, dated October 5, 2012 and previously amended on June 28, 2013, with Intrexon (as amended, the “Channel
Agreement”), pursuant to which Intrexon is licensing additional rights to certain technology to the Company; and 
 B. In
consideration of such additional license to the Company under the Channel Agreement, the Company has agreed to issue to Intrexon certain shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) in
accordance with the terms and conditions of this Agreement. 
 C. The parties have previously entered into a Registration Rights
Agreement, dated October 5, 2013 (the “Rights Agreement”). 
 NOW THEREFORE, in consideration of the mutual
covenants contained in this Agreement and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Company and Intrexon hereby agree as follows: 

 

	SECTION 1.	AUTHORIZATION OF ISSUANCE OF SHARES.  

1.1 Supplemental Access Fee Shares. Subject to the terms and conditions of this Agreement, the Company has authorized the
issuance to Intrexon of that number of shares of the Company’s Common Stock having a Fair Market Value of $5,000,000 (“Supplemental Access Fee Shares”) at the Closing (as hereinafter defined). 

1.2 Calculation of Fair Market Value. “Fair Market Value” of the Common Stock for purposes of calculating the
number of Supplemental Access Fee Shares shall be the per share closing sales price of the Common Stock, as reported by the NYSE MKT, on the trading day immediately preceding the date of the Amendment. 

1.3 Capital Adjustments. If after the date hereof and prior to the date the Supplemental Access Fee Shares are issued
(i) the outstanding shares of the Company’s Common Stock shall be subdivided or split into a greater number of shares or a dividend in Common Stock shall be paid in respect of such Common Stock or (ii) the outstanding shares of Common
Stock are combined, then all share quantities in this Agreement not yet issued shall be appropriately adjusted to reflect such stock split, stock dividend or conjunction. 

  
 1 

 EXECUTION COPY 

CONFIDENTIAL 
  

	SECTION 2.	CLOSING AND DELIVERY 

 2.1
Issuance of Supplemental Access Fee Shares. Subject to the terms and conditions of this Agreement and the Channel Agreement, as amended, and in reliance upon the representations, warranties and agreements contained herein, the
Company will issue to Intrexon the Supplemental Access Fee Shares. The Parties agree that the consideration received by the Company hereunder shall be the execution and delivery by Intrexon of the Amendment which consideration is at least equal to
the par value of the Supplemental Access Fee Shares issued hereunder. 
 2.2 Closing. The closing of the issuance of the
Supplemental Access Fee Shares shall be held at the offices of the Company or at such other place as the Company and Intrexon may agree, and shall occur, subject to the conditions set forth in Section 8 hereof and applicable to the Supplemental
Access Fee Shares Closing, on such other date as Intrexon and the Company may agree upon but in no event later than January 24, 2014 (the “Closing”). 

2.3 Delivery of the Shares. Promptly following the Closing, the Company shall deliver to Intrexon a certificate representing the
Supplemental Access Fee Shares required to be issued the Closing, registered in the name of Intrexon. 
  

	SECTION 3.	REPRESENTATIONS AND WARRANTIES OF THE COMPANY.  

Subject to and except as set forth in the SEC Documents, the Company hereby represents and warrants to Intrexon as of the date hereof as
follows: 
 3.1 Organization, Good Standing and Power. The Company is a corporation duly incorporated, validly existing and in
good standing under the laws of the State of Delaware and has the requisite corporate power to own, lease and operate its properties and assets and to conduct its business as it is now being conducted and as described in the reports filed by the
Company with the Securities and Exchange Commission (the “Commission”) pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), since the end of its most
recently completed fiscal year through the date hereof, including, without limitation, its most recent report on Form 10-Q. The Company does not have any subsidiaries other than those identified in its most recent report on Form 10-Q. The Company is
qualified to do business as a foreign corporation and is in good standing in every jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except for any jurisdiction(s) (alone or in the
aggregate) in which the failure to be so qualified will not have a Material Adverse Effect. For the purposes of this Agreement, “Material Adverse Effect” means any effect on the business, operations, properties or financial
condition of the Company that is material and adverse to the Company, taken as a whole, and any condition, circumstance or situation that would prohibit the Company from entering into and performing any of its obligations hereunder. 

3.2 Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and perform this
Agreement and to issue the shares in accordance with the terms hereof. The execution, delivery and performance of this Agreement by the Company and the consummation by it of the transactions contemplated hereby have been duly and validly

  
 2 

 EXECUTION COPY 

CONFIDENTIAL 
  

 
authorized by all necessary corporate action, and no further consent or authorization of the Company, its board of directors or stockholders is required, except pursuant to Section 8. When
executed and delivered by the Company, this Agreement shall constitute a valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy,
reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of general application. The
Company’s board of directors, at a meeting duly called and held, adopted resolutions approving the transactions contemplated hereby, including the issuance of the Supplemental Access Fee Shares. 

3.3 Issuance of Shares. The shares to be issued and sold hereunder have been duly authorized by all necessary corporate action
and, when issued in accordance with the terms hereof, will be validly issued, fully paid and nonassessable. In addition, such shares will be free and clear of all liens, claims, charges, security interests or agreements, pledges, assignments,
covenants, restrictions or other encumbrances created by, or imposed by, the Company (collectively, “Encumbrances”) and rights of refusal of any kind imposed by the Company (other than restrictions on transfer under applicable
securities laws) and the holder of such shares shall be entitled to all rights accorded to a holder of Common Stock. 
 3.4 No
Conflicts; Governmental Approvals. The execution, delivery and performance of the Agreement by the Company and the consummation by the Company of the transactions contemplated hereby do not and will not (i) violate any provision of the
Company’s Articles of Incorporation or Bylaws, each as amended to date, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of
termination, amendment, acceleration or cancellation of, any agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement, instrument or obligation to which the Company is a party or by which the Company’s properties or
assets are bound, or (iii) result in a violation of any federal, state, local or foreign statute, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations) applicable to the Company or by which
any property or asset of the Company is bound or affected, except for such conflicts, defaults, terminations, amendments, acceleration, cancellations and violations as would not, individually or in the aggregate, have a Material Adverse Effect. The
Company is not required under federal, state, foreign or local law, rule or regulation to obtain any consent, authorization or order of, or make any filing or registration with, any court or governmental agency in order for it to execute, deliver or
perform any of its obligations under this Agreement or issue and sell the shares in accordance with the terms hereof (other than any filings, consents and approvals which may be required to be made by the Company under applicable state and federal
securities laws, rules or regulations prior to or subsequent to the Closing). 
 3.5 Commission Documents, Financial
Statements. The Common Stock of the Company is registered pursuant to Section 12(b) of the Exchange Act. During the year preceding this Agreement, the Company has timely filed all reports, schedules, forms, statements and other documents
required to be filed by it with the Commission pursuant to the reporting requirements of the Exchange Act (such filings, including such filings made on the date of this Agreement, the “SEC Documents”). At the times of their
respective filing, all such reports, schedules, forms, statements and other documents complied in all material respects with the 

  
 3 

 EXECUTION COPY 

CONFIDENTIAL 
  

 
requirements of the Exchange Act and the rules and regulations of the Commission promulgated thereunder. At the times of their respective filings, such reports, schedules, forms, statements and
other documents did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made,
not misleading. As of their respective dates, the financial statements of the Company included in the SEC Documents complied in all material respects with applicable accounting requirements and the published rules and regulations of the Commission
or other applicable rules and regulations with respect thereto. Such financial statements have been prepared in accordance with generally accepted accounting principles applied on a consistent basis during the periods involved (except (i) as
may be otherwise indicated in such financial statements or the notes thereto or (ii) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed or summary statements), and fairly present in all
material respects the consolidated financial position of the Company as of the dates thereof and the results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit
adjustments). 
 3.6 Accountants. BDO USA LLP, whose report on the financial statements of the Company is filed with the SEC
in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012, were, at the time such report was issued, independent registered public accountants as required by the Securities Act of 1933 and the rules and regulations
promulgated thereunder (together, the “Securities Act”).  
 3.7 Internal Controls. The Company has
established and maintains a system of internal accounting controls sufficient to provide reasonable assurances that: (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles in the United States and to maintain accountability for assets; (iii) access to assets is permitted only in
accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences. 

3.8 Disclosure Controls. The Company has established and maintains disclosure controls and procedures (as such term is defined
in Rules 13a-15 and 15d-15 under the Exchange Act). Since the date of the most recent evaluation of such disclosure controls and procedures, there have been no significant changes in internal controls or in other factors that could significantly
affect internal controls, including any corrective actions with regard to significant deficiencies and material weaknesses. The Company is in compliance in all material respects with all provisions currently in effect and applicable to the Company
of the Sarbanes-Oxley Act of 2002, and all rules and regulations promulgated thereunder or implementing the provisions thereof. 
 3.9
No Material Adverse Change. Except as disclosed in the SEC Documents or as a result of the Equity Financing (including any conditions precedent to completing such Equity Financing), since November 14, 2013, the Company has not
(i) experienced or suffered any Material Adverse Effect, (ii) incurred any material liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) other
than those incurred in the ordinary course of the Company’s business or (iii) declared, made or paid any dividend or distribution of any kind on its capital stock. 

  
 4 

 EXECUTION COPY 

CONFIDENTIAL 
  

 3.10 No Undisclosed Events or Circumstances. Except as disclosed in the SEC
Documents, since November 14, 2013, except for the consummation of the transactions contemplated herein, to the Company’s knowledge, no event or circumstance has occurred or exists with respect to the Company or its businesses, properties,
prospects, operations or financial condition, which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced or disclosed. 

3.11 Litigation. No action, suit, proceeding or investigation is currently pending or, to the knowledge of the Company, has been
threatened in writing against the Company that: (i) concerns or questions the validity of this Agreement; (ii) concerns or questions the right of the Company to enter into this Agreement; or (iii) is reasonably likely to have a
Material Adverse Effect. The Company is neither a party to nor subject to the provisions of any material order, writ, injunction, judgment or decree of any court or government agency or instrumentality. There is no action, suit, proceeding or
investigation by the Company currently pending or that the Company intends to initiate that would have a Material Adverse Effect. 
 3.12
Compliance. Except for defaults or violations which are not reasonably likely to have a Material Adverse Effect, the Company is not (i) in default under or in violation of (and no event has occurred that has not been waived that,
with notice or lapse of time or both, would result in a default by the Company under), nor has the Company received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other
agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any order of any court, arbitrator or governmental body, or
(iii) is or has been in violation of any statute, rule or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws, applicable to its business, except in each case for such defaults or
violations as would not have a Material Adverse Effect. 
 3.13 Intellectual Property. The Company and its United States
subsidiaries (“Subsidiaries”) solely own, or, to the knowledge of the Company, possess valid and enforceable licenses to use or sublicense inventions, copyrights, know-how (including trade secrets and other unpatented and/or
unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks and trade names, patents and patent rights and other intellectual property (collectively “Intellectual Property”) material to
carrying on their businesses as described in the SEC Documents (collectively, “Company Intellectual Property”), such ownership and, to the knowledge of the Company, such licenses, being free and clear of all liens, encumbrances and
defects and challenges by others, except such as are described in the SEC Documents, and the Company has taken all reasonable steps to secure its interests in the Company Intellectual Property, including obtaining assignments of owned Company
Intellectual Property from its employees and contractors. Issued patents within the Company Intellectual Property, together with patent applications within the Company Intellectual Property, if such patent applications result in issued patents with
claims having substantially the same scope as the claims of such patent applications as of the date hereof, claim the Company’s current marketed products and products in development, for the indications

  
 5 

 EXECUTION COPY 

CONFIDENTIAL 
  

 
currently approved and currently being developed. Neither the Company nor any Subsidiary has received any written correspondence relating to or asserting rights in any Company Intellectual
Property, or written notice of infringement, misappropriation or violation of asserted rights of others in any Intellectual Property, which, in either case, would render any Company Intellectual Property invalid or unenforceable or bring into
question the Company’s and the Subsidiaries’ ownership of any Company Intellectual Property. To the knowledge of the Company, the conduct and the proposed conduct of the businesses of the Company and its Subsidiaries, including the
research, development, manufacture, sale and use of its current products and its products in development, as described in the SEC Documents, does not, and is not reasonably expected to, infringe or misappropriate the valid Intellectual Property
rights of any third party. The Company is not aware of any facts or circumstances that would reasonably be expected to render any Company Intellectual Property invalid or unenforceable, and the Company is not aware of any material commercial
infringement or misappropriation by any third party of any Company Intellectual Property. None of the Company Intellectual Property is or has been involved in any opposition, cancellation, interference, reissue or reexamination proceeding and no
Company Intellectual Property is the subject of any judicial, administrative or arbitral order, award, decree, injunction, lawsuit, proceeding or stipulation, other than review by patent offices of pending applications for patents in the ordinary
course or review in connection with potential extension of patent term. There are no outstanding options, licenses or agreements of any kind that have been entered into by the Company, and to the knowledge of the Company, by any third party, that
relate to the Company Intellectual Property that are required by applicable law to be described in the SEC Documents that are not described therein in all material respects. None of the Intellectual Property used by the Company or any of the
Subsidiaries has been obtained or is being used by the Company or its Subsidiaries in violation of any contractual obligation binding on the Company, any of the Subsidiaries or, to the knowledge of the Company, any of the officers, directors or
employees of the Company or any of the Subsidiaries, other than such violations as would not individually or in the aggregate if the subject of an unfavorable decision, ruling or finding, reasonably be expected to have a Material Adverse Effect.
“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other
entity of any kind. 
 3.14 FDA Compliance. Except as
described in the SEC Documents, and except as would not, individually or in the aggregate, have or would reasonably be expected to have a Material Adverse Effect (i) neither the Company nor any of the Subsidiaries has received any unresolved
FDA Form 483, warning letter or untitled letter from the U.S. Food and Drug Administration (“FDA”), or any other court or arbitrator or federal, state, local or foreign governmental or regulatory authority, alleging or asserting
noncompliance with the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 301 et seq.) (the “FFDCA”) or similar law, (ii) the Company and each of the Subsidiaries is and has been in compliance with applicable health care
laws, including without limitation, the FFDCA, the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)(2)), the civil False Claims Act (31 U.S.C. §§ 3729(a) et seq.), the administrative False Claims Law (42 U.S.C. §
1320a-7b(a)), the Anti-Inducement Law (42 U.S.C. § 1320a-7a(a)(5)), the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.), and the Patient Protection and Affordable Care Act of 2010 (Public Law
111-148), as amended by the Health Care and Education Affordability Reconciliation Act of 2010 (Public Law 111-152), and the regulations promulgated pursuant to such laws, and comparable state 

  
 6 

 EXECUTION COPY 

CONFIDENTIAL 
  

 
laws, and all other local, state, federal, national, supranational and foreign laws, manual provisions and written administrative guidance relating to the regulation of the Company (collectively,
“Health Care Laws”), (iii) the Company and each of the Subsidiaries possesses all licenses, certificates, approvals, clearances, authorizations and permits required by any such Health Care Laws and/or to carry on its businesses
as now conducted (“Authorizations”) and such Authorizations are valid and in full force and effect and the Company is not in violation of any term of any such Authorizations, (iv) neither the Company nor any of the Subsidiaries
has received written notice of any ongoing claim, action, suit, proceeding, hearing, enforcement action, investigation or arbitration from any U.S. or non-U.S. federal, state, local or other governmental or regulatory authority, governmental or
regulatory agency or body, court or arbitrator (each, a “Governmental Authority”) or third party alleging that any product operation or activity is in violation of any Health Care Laws or Authorizations or has any knowledge that any
such Governmental Authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding, (v) neither the Company nor any of the Subsidiaries has received written notice that any Governmental
Authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any Authorizations or has any knowledge that any such Governmental Authority is considering such action, (vi) the Company and each of the Subsidiaries
has filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws or Authorizations and that all such reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments were complete, correct and not misleading on the date filed (or were corrected or supplemented by a subsequent submission), and (vii) neither the Company
nor any of the Subsidiaries has, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement, safety alert (but excluding adverse event reports in
clinical trials), post sale warning, “dear doctor” letter, or other notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to the Company’s knowledge, no
third party has initiated or conducted any such notice or action. 
 3.15 Application of Takeover Protections. The issuance of
the Supplemental Access Fee Shares hereunder and Intrexon’s ownership thereof is not prohibited by the business combination statutes of the state of Delaware. The Company has not adopted any stockholder rights plan, “poison pill” or
similar arrangement that would trigger any right, obligation or event as a result of the issuance of such Supplemental Access Fee Shares and Intrexon’s ownership of such shares and there are no similar anti-takeover provisions under the
Company’s charter documents. 
 3.16 Listing and Maintenance Requirements. The Company is in compliance with the
requirements of the NYSE MKT for continued listing of the Common Stock thereon. The issuance and sale of the shares hereunder does not contravene the rules and regulations of the NYSE MKT. 

3.17 Private Placement. Neither the Company nor its Affiliates, nor any Person acting on its or their behalf, (i) has
engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under the Securities Act) in connection with the offer or sale of the shares hereunder, (ii) has, directly or indirectly, made any offers or
sales of any 

  
 7 

 EXECUTION COPY 

CONFIDENTIAL 
  

 
security or solicited any offers to buy any security, under any circumstances that would require registration of the sale and issuance by the Company of the shares under the Securities Act or
(iii) has issued any shares of Common Stock or shares of any series of preferred stock or other securities or instruments convertible into, exchangeable for or otherwise entitling the holder thereof to acquire shares of Common Stock which would
be integrated with the sale of the shares to Intrexon for purposes of requiring registration of such shares pursuant to the Securities Act or for the purpose of any applicable stockholder approval provisions, including, without limitation, under the
rules and regulations of any exchange or automated quotation system on which any of the securities of the Company are listed or designated, nor will the Company or any of its subsidiaries or affiliates take any action or steps that would require
registration of any of the shares under the Securities Act or cause the offering of the shares to be integrated with other offerings. Assuming the accuracy of the representations and warranties of Intrexon, the offer and issuance of the shares by
the Company to Intrexon pursuant to this Agreement will be exempt from the registration requirements of the Securities Act. 
 3.18
No Manipulation of Stock. The Company has not taken, and has no plans to take, in violation of applicable law, any action outside the ordinary course of business designed to, or that might reasonably be expected to, cause or result in
unlawful manipulation of the price of the Common Stock. 
 3.19 Brokers. Neither the Company nor any of the officers,
directors or employees of the Company has employed any broker or finder in connection with the transaction contemplated by this Agreement. The Company shall indemnify Intrexon from and against any broker’s, finder’s or agent’s fees
for which the Company is responsible. 
  

	SECTION 4.	REPRESENTATIONS, WARRANTIES AND COVENANTS OF INTREXON. 

4.1 Purchaser Sophistication. Intrexon represents and warrants to, and covenants with, the Company that Intrexon (a) is
knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to, investments in shares presenting an investment decision like that involved in the acceptance of the shares pursuant hereto, including
investments in securities issued by the Company and investments in comparable companies, and has requested, received, reviewed and considered all information it deemed relevant in making an informed decision to purchase the shares,
(b) Intrexon, in connection with its decision to purchase the shares, relied only upon the SEC Documents, other publicly available information, and the representations and warranties of the Company contained herein. Intrexon is an
“accredited investor” pursuant to Rule 501 of Regulation D under the Securities Act, (c) Intrexon is acquiring the shares for its own account for investment only and with no present intention of distributing any of such shares or any
arrangement or understanding with any other persons regarding the distribution of such shares; (d) Intrexon has not been organized, reorganized or recapitalized specifically for the purpose of investing in the shares; (e) Intrexon will
not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire to take a pledge of) any of the shares except in compliance with the Securities Act and applicable state
securities laws, (f) Intrexon understands that the shares are being offered and sold to it in reliance upon specific exemptions from the registration requirements of the Securities Act and state securities laws, and that the Company is relying
upon the truth and accuracy of, and Intrexon’s compliance with, the representations, warranties, 

  
 8 

 EXECUTION COPY 

CONFIDENTIAL 
  

 
agreements, acknowledgments and understandings of Intrexon set forth herein in order to determine the availability of such exemptions and the eligibility of Intrexon to acquire the shares,
(g) Intrexon understands that its investment in the shares involves a significant degree of risk, including a risk of total loss of Intrexon’s investment (provided that such acknowledgment in no way diminishes the representations,
warranties and covenants made by the Company hereunder) and (h) Intrexon understands that no United States federal or state agency or any other government or governmental agency has passed upon or made any recommendation or endorsement of the
shares. 
 4.2 Authorization and Power. Intrexon has the requisite power and authority to enter into and perform this
Agreement. The execution, delivery and performance of this Agreement by Intrexon and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary corporate action, and no further consent or authorization
of Intrexon or its board of directors or stockholders is required. When executed and delivered by Intrexon, this Agreement shall constitute a valid and binding obligation of Intrexon enforceable against Intrexon in accordance with its terms, except
as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s rights and
remedies or by other equitable principles of general application. 
 4.3 No Conflict. The execution, delivery and performance
of this Agreement by Intrexon and the consummation by Intrexon of the transactions contemplated hereby do not and will not (i) violate any provision of Intrexon’s charter or organizational documents, (ii) conflict with, or constitute
a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, mortgage, deed of trust, indenture, note, bond,
license, lease agreement, instrument or obligation to which Intrexon is a party or by which Intrexon’s properties or assets are bound, or (iii) result in a violation of any federal, state, local or foreign statute, rule, regulation, order,
judgment or decree (including federal and state securities laws and regulations) applicable to Intrexon or by which any property or asset of Intrexon are bound or affected, except, in all cases, other than violations (with respect to federal and
state securities laws) above, for such conflicts, defaults, terminations, amendments, acceleration, cancellations and violations as would not, individually or in the aggregate, materially and adversely affect Intrexon’s ability to perform its
obligations under the Agreement. 
 4.4 Restricted Shares. Intrexon acknowledges that the shares when issued shall be
restricted securities and must be held indefinitely unless subsequently registered under the Securities Act or the Company receives an opinion of counsel reasonably satisfactory to the Company that such registration is not required. Intrexon is
aware of the provisions of Rule 144 promulgated under the Securities Act which permit limited resale of stock purchased in a private placement subject to the satisfaction of certain conditions, including, among other things, the existence of a
public market for the stock, the availability of certain current public information about the Company, the resale occurring not less than one year after a party has purchased and paid for the stock to be sold, the sale being through a
“broker’s transaction” or a transaction directly with a “market maker” and the number of shares of the stock being sold during any three-month period not exceeding specified limitations. Intrexon further acknowledges and
understands that the Company may not be satisfying the current public information requirement 

  
 9 

 EXECUTION COPY 

CONFIDENTIAL 
  

 
of Rule 144 at the time Intrexon wishes to sell the shares and, if so, Intrexon would be precluded from selling the shares under Rule 144 even if the one year minimum holding period has been
satisfied. 
 4.5 Stock Legends. Intrexon acknowledges that certificates evidencing the Supplemental Access Fee Shares shall
bear a restrictive legend in substantially the following form (and including related stock transfer instructions and record notations): 

4.6 THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN
RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT
OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL
REASONABLY SATISFACTORY TO THE COMPANY. 
 4.7 Brokers. Neither Intrexon nor any of the officers, directors or
employees of Intrexon has employed any broker or finder in connection with the transaction contemplated by this Agreement. Intrexon shall indemnify the Company from and against any broker’s, finder’s or agent’s fees for which Intrexon
is responsible. 
  

	SECTION 5.	INDEMNIFICATIONS. 

 5.1 Indemnification by the Company. The
Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless Intrexon, its permitted assignees, officers, directors, agents, Affiliates and employees, to the fullest extent permitted by applicable law, from and
against any and all claims, losses, damages, liabilities, penalties, judgments, costs and expenses (including, without limitation, reasonable attorneys’ fees and expenses) (collectively, “Losses”), arising out of or relating to
any untrue or alleged untrue statement of a material fact contained in a Registration Statement (as defined in the Rights Agreement) or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein
or necessary to make the statements therein (in the case of any prospectus or form of prospectus or supplement thereto, in the light of the circumstances under which they were made) not misleading, except (i) to the extent that such untrue
statements or omissions are based upon information furnished to the Company by Intrexon expressly for use in the Registration Statement; (ii) as a result of the failure of such indemnitee to deliver a prospectus, as amended or supplemented, to
a purchaser in connection with an offer or sale; or (iii) the use by the indemnitee of an outdated or defective prospectus after the Company has notified Intrexon in writing that the prospectus is outdated or defective, but only if and to the
extent that following such receipt the misstatement or omission giving rise to such Loss would have been corrected; provided, however, that the indemnity agreement contained in this Section 5.1 shall not apply to amounts paid in settlement of
any Losses if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld. 

  
 10 

 EXECUTION COPY 

CONFIDENTIAL 
  

 5.2 Indemnification by Intrexon. Intrexon shall indemnify and hold harmless the
Company, its directors, officers, agents and employees to the fullest extent permitted by applicable law, from and against all Losses, as incurred, arising out of or relating to any untrue or alleged untrue statement of a material fact contained in
a Registration Statement or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or supplement thereto, in the
light of the circumstances under which they were made) not misleading, to the extent that such untrue statement or omission is contained in or omitted from any information regarding Intrexon furnished in writing to the Company by Intrexon expressly
for use in therein, and that such information was reasonably relied upon by the Company for use therein, or to the extent that such information relates to Intrexon or Intrexon’s proposed method of distribution of shares and was furnished in
writing by Intrexon expressly for use therein. Notwithstanding anything to the contrary contained herein, in no event shall the liability of Intrexon under this Section 5.2 exceed the net proceeds to Intrexon as a result of the sale of shares
pursuant to a Registration Statement in connection with which the untrue or alleged untrue statement or material omission was provided. 
  

	SECTION 6.	SURVIVAL OF REPRESENTATIONS, WARRANTIES AND AGREEMENTS. 

Notwithstanding any investigation made by any party to this Agreement, all representations and warranties made by the Company and Intrexon
herein shall survive the execution of this Agreement and the issuance to Intrexon of the Supplemental Access Fee Shares and shall terminate one (1) year after the Closing, provided, however, that the representations and warranties in Sections
3.1, 3.2, 3.3 and 3.4 shall survive for so long as Intrexon continues to hold any of the Supplemental Access Fee Shares issued hereunder. No claim may be asserted against either party for breach of any representation or warranty contained herein,
unless written notice of such claim is received by such party describing in reasonable detail and to the extent available the facts and circumstances with respect to the subject matter of such claim on or prior to the date on which the
representation or warranty on which such claim is based ceases to survive as set forth above. In no event shall any party be liable to the other party for any punitive, incidental, consequential, special or indirect damages, including loss of future
revenue or income, loss of business reputation or opportunity relating to the breach or alleged breach of any representation or warranty in this Agreement. 
  

	SECTION 7.	COVENANTS.  

 7.1 Notifications. 

(a) During the period prior to the Closing, the Company will promptly advise Intrexon in writing of (i) any Material Adverse
Effect, or (ii) any notice or other communication from any third person or entity alleging that the consent of the third person is required in connection with the transactions contemplated by this Agreement. 

(b) Information received by Intrexon pursuant to this Section 7.1 shall be considered “Confidential Information” as such
term is defined in the Channel Agreement and Intrexon agrees to treat such information in accordance with the provisions of Article 7 of the Channel Agreement. 

  
 11 

 EXECUTION COPY 

CONFIDENTIAL 
  

 7.2 Best Efforts. Each party will use its reasonable best efforts to satisfy in
a timely fashion each of the conditions to be satisfied by it under Section 8 of this Agreement. 
 7.3 No Poison Pill.
The Company will not adopt any stockholder rights plan, “poison pill” or similar arrangement, or adopt any anti-takeover provisions under its charter documents, that would trigger any right, obligation or event as a result of the issuance
of the Shares hereunder to Intrexon or Intrexon’s ownership of such Shares or the accumulation of shares of Common Stock acquired in the market by Intrexon or its affiliates. 

7.4 Approval. In each case where the Company determines that the approval of any exchange or other listing upon which the Common
Stock may be listed is required for the issuance of Common Stock to Intrexon, the Company shall use commercially reasonable efforts to secure such approval as promptly as possible. In the event, notwithstanding the foregoing obligation, the Company
is unable to secure the approval with respect to the issuance of any Shares to be issued hereunder, the Company shall negotiate the terms of an alternate form of consideration of equivalent value to such unissued shares. 

7.5 Further Assurances. Each of the Company and Intrexon shall do and perform, or cause to be done and performed, all such
further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as each other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement, the
Channel Agreement and the consummation of the transactions contemplated thereby. 
  

	SECTION 8.	CONDITIONS TO CLOSING.  

8.1 The obligation hereunder of the Company to issue shares to Intrexon at the Closing is subject to the satisfaction or waiver, at or
before the Closing of the conditions set forth below. These conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion. 

(a) Accuracy of Intrexon’s Representations and Warranties. The representations and warranties of Intrexon shall be true and
correct as of the date when made and as of the Closing Date as though made at that time, except for representations and warranties that are expressly made as of a particular date, which shall be true and correct as of such date. 

(b) Performance by Intrexon. Intrexon shall have performed, satisfied and complied in all material respects with all covenants,
agreements and conditions required by this Agreement and the Channel Agreement to be performed, satisfied or complied by Intrexon at or prior to the Closing Date. 

  
 12 

 EXECUTION COPY 

CONFIDENTIAL 
  

 (c) Amendment to Channel Agreement. The Amendment shall have been entered into
by the Company and Intrexon and the Channel Agreement shall be in full force and effect. 
 (d) No Injunction. No statute,
rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of any of the transactions
contemplated by this Agreement. 
 (e) No Proceedings or Litigation. No action, suit or proceeding before any arbitrator or
any governmental authority shall have been commenced, and no investigation by any governmental authority shall have been threatened in writing against Intrexon or any of the officers, directors or Affiliates of Intrexon seeking to restrain, prevent
or change the transactions contemplated by this Agreement, the Channel Agreement or seeking damages in connection with such transactions. 

(f) NYSE MKT Approval. The Company shall have received approval for the listing of the Supplemental Access Fee Shares on the
NYSE MKT. 
 8.2 The obligation hereunder of Intrexon to receive Shares and consummate the transactions contemplated by this
Agreement is subject to the satisfaction or waiver, at or before Closing, of each of the conditions set forth below. These conditions are for Intrexon’s sole benefit and may be waived by Intrexon at any time in its sole discretion. 

(a) Accuracy of the Company’s Representations and Warranties. Each of the representations and warranties of the Company in
this Agreement shall be true and correct as of the Closing Date, except for representations and warranties that speak as of a particular date, which shall be true and correct as of such date. 

(b) Performance by the Company. The Company shall have performed, satisfied and complied in all material respects with all
covenants, agreements and conditions required by this Agreement and the Channel Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date. 

(c) Channel Partnership Agreement. The Amendment shall have been entered into by the Company and Intrexon and the Channel
Agreement shall be in full force and effect. 
 (d) No Injunction. No statute, rule, regulation, executive order, decree,
ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of any of the transactions contemplated by this Agreement or the Channel
Agreement. 
 (e) No Proceedings or Litigation. No action, suit or proceeding before any arbitrator or any governmental
authority shall have been commenced, and no investigation by any governmental authority shall have been threatened in writing against the Company or any of the officers, directors or Affiliates of the Company seeking to restrain, prevent or change
the transactions contemplated by this Agreement, the Channel Agreement or seeking damages in connection with such transactions. 
 (f)
No Material Adverse Effect. Since the date of this Agreement, there shall not have occurred any Material Adverse Effect. 

  
 13 

 EXECUTION COPY 

CONFIDENTIAL 
  

	SECTION 9.	NOTICES.  

 All notices or other communications which are required
or permitted hereunder shall be in writing and addressed as follows: 
  

			
	If to the Company:	  	Fibrocell Science, Inc.
		  	405 Eagleview Boulevard
		  	Exton, PA 19341
		  	Attention: Chief Executive Officer
		  	Fax No.: (484) 713-6001
		
	If to Intrexon:	  	Intrexon Corporation
		  	20374 Seneca Meadows Parkway
		  	Germantown, MD 20876
		  	Attention: Legal Department
		  	Fax No.: (301) 556-9902

 or to such other address as the party to whom notice is to be given may have furnished to the other party in writing in
accordance herewith. Any such communication shall be deemed to have been given when delivered if personally delivered or sent by facsimile (provided that the party providing such notice promptly confirms receipt of such transmission with the other
party by telephone), on the business day after dispatch if sent by a nationally-recognized overnight courier and on the third business day following the date of mailing if sent by certified mail, postage prepaid, return receipt requested. 

 

	SECTION 10.	MISCELLANEOUS. 

 10.1 Fees and
Expenses. Each party shall pay the fees and expenses of its advisors, counsel, accountants and other experts, if any, and all other expenses, incurred by such party incident to the negotiation, preparation, execution, delivery and performance of
this Agreement. 
 10.2 Waivers and Amendments. Neither this Agreement nor any provision hereof may be changed, waived,
discharged, terminated, modified or amended except upon the written consent of the parties hereto. 
 10.3 Headings. The
headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not be deemed to be part of this Agreement. 

10.4 Severability. If any provision hereof should be held invalid, illegal or unenforceable in any respect, then, to the fullest
extent permitted by law, (a) all other provisions hereof shall remain in full force and effect and shall be liberally construed in order to carry out the intentions of the Parties as nearly as may be possible and (b) the parties shall use
their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of such provision(s) in this Agreement. 

  
 14 

 EXECUTION COPY 

CONFIDENTIAL 
  

 10.5 Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware as applied to contracts entered into and performed entirely in the State of Delaware by Delaware residents, without regard to conflicts of law principles. 

10.6 Counterparts. This Agreement may be executed in two or more counterparts (including by facsimile, PDF, or other means of
electronic communication), each of which shall constitute an original, but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and
delivered to the other parties. 
 10.7 Successors and Assigns. Except as otherwise expressly provided herein, the provisions
hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto, provided that Intrexon shall not assign its rights or obligations hereunder unless Intrexon assigns such
rights in whole and not in part to an assignee of such rights and obligations which shall agree in writing with the Company to be bound by this Agreement. 

10.8 No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective
permitted successors and assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person. 
 10.9
Entire Agreement. This Agreement, the Amendment, the Channel Agreement, the Rights Agreement and other documents executed and delivered pursuant hereto and thereto, including the exhibits, constitute the full and entire understanding and
agreement between the parties with regard to the subjects hereof and thereof. 
 10.10 Publicity. Except as otherwise provided
herein or in the Channel Agreement, no party shall issue any press releases or otherwise make any public statement with respect to the transactions contemplated by this Agreement without the prior written consent of the other party, except as may be
required by applicable law or regulations, in which case such party shall provide the other parties with reasonable notice of such publicity and/or opportunity to review such disclosure. 

10.11 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review,
drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

  
 15 

 EXECUTION COPY 

CONFIDENTIAL 
  

 IN WITNESS WHEREOF, the parties hereto
have caused this Supplemental Stock Issuance Agreement to be executed by their duly authorized representatives as of the day and year first above written. 
  

					
		 	FIBROCELL SCIENCE, INC.
			
		 	By:	 	 /s/ David Pernock

		 	Name:	 	David Pernock
		 	Title:	 	CEO/Chairman
		
		 	INTREXON CORPORATION
			
		 	By:	 	 /s/ Gregory Frost

		 	Name:	 	Gregory Frost
		 	Title:	 	SVP Health Sector

 SIGNATURE PAGE FOR SUPPLEMENTAL STOCK ISSUANCE AGREEMENT 

  
 16EX-10.1

 Exhibit 10.1 
 Execution Copy 
 THIRD AMENDED AND RESTATED REGISTRATION RIGHTS
AGREEMENT 
 This Third Amended and Restated Registration Rights Agreement (this “Agreement”) is entered
into as of June 1, 2009 by and among Concert Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), and the persons and entities listed on signature pages hereto (the “Investors”) and amends and
restates the Second Amended and Restated Registration Rights Agreement (the “Original Agreement”) dated as of April 25, 2008 by and among the Corporation and the persons and entities listed on the signature pages thereto (the
“Prior Investors”). 
 WHEREAS, the Corporation has entered into that certain Series D Convertible Preferred
Stock Purchase Agreement (the “Series D Purchase Agreement”) with one of the Investors (the “Purchasing Investor”), pursuant to which, on the date hereof, the Corporation is issuing Series D Convertible
Preferred Stock, par value $0.001 per share (the “Series D Preferred Stock”), to the Purchasing Investor. 

WHEREAS, the Purchasing Investor has required, as a condition to the purchase of the Series D Preferred Stock pursuant to the Series D
Purchase Agreement and consistent with Section 6.7 thereof, that it be granted registration rights with respect to the shares of Common Stock issuable upon conversion of the shares of Series D Preferred Stock as set forth herein. 

WHEREAS, the Corporation and the Prior Investors are parties to the Original Agreement pursuant to which the Corporation granted to the
Prior Investors certain registration rights as set forth in the Original Agreement. 
 WHEREAS, the Corporation and the Prior
Investors desire to amend and restate the Original Agreement on the terms set forth herein in order to grant to the Purchasing Investor the registration rights set forth herein, and the Prior Investors accept the rights created pursuant hereto in
lieu of the rights granted to them under the Original Agreement. 
 WHEREAS, in accordance with Section 20(b) of the
Original Agreement, this Agreement has been executed by the Corporation and the Holders (as defined in the Original Agreement) of at least 60% in voting power of the Series B Convertible Preferred Stock, par value $0.001 per share (the
“Series B Preferred Stock”), of the Corporation and the Series C Convertible Preferred Stock, par value $0.001 per share (the “Series C Preferred Stock”), of the Corporation, voting together as a single class as if
converted to shares of the Corporation’s Common Stock, par value $0.001 per share (the “Common Stock”). 

NOW, THEREFORE, in consideration of the premises and the mutual agreements hereinafter set forth, the parties hereby agree as follows:

 SECTION 1. Definitions. As used in this Agreement, the following terms shall have the following meanings: 

(a) The term “1934 Act” means the Securities Exchange Act of 1934, as amended. 

(b) The “Affiliate” of any Holder (or any transferee of any Holder) means any general or limited partner of any Holder
(or transferee) that is a partnership, any member of any 

 
Holder that is a limited liability company or any person or entity that, directly or indirectly, through one or more intermediaries, controls, or is controlled by, or is under common control
with, such Holder or transferee, including, without limitation, any venture capital fund now or hereafter existing of which the Holder or transferee is a partner or member which is controlled by or under common control with one or more general
partners of such Holder or transferee or shares the same management company with such Holder or transferee. 
 (c) The term
“Holder” means any holder of Registrable Shares. 
 (d) The term “Preferred Stock” shall mean
the Corporation’s Series A Convertible Preferred Stock, par value $0.001 per share, the Series B Preferred Stock, the Series C Preferred Stock and the Series D Preferred Stock. 

(e) The terms “register,” “registered,” and “registration” refer to a registration
effected by preparing and filing a registration statement in compliance with the Securities Act and the declaration or ordering of effectiveness of such registration statement. 

(f) The term “Registrable Shares” means (1) the Common Stock issuable upon conversion of the Preferred Stock,
(2) any Common Stock purchased by an Investor (or its permitted transferees) pursuant to Section 3 of the Third Amended and Restated Investor Rights Agreement of even date herewith by and among the Corporation and the Investors (or Common
Stock issuable with respect to other securities so purchased), and (3) any Common Stock issued as a dividend or other distribution with respect to, or in exchange or in replacement of, such Preferred Stock or Common Stock, provided that any
Registrable Shares shall cease to be Registrable Shares if transferred by an Investor other than in compliance with the provisions of Section 15 hereof. 
 (g) The term “Rule 144” means Rule 144 promulgated under the Securities Act. 
 (h) The term “SEC” means the Securities and Exchange Commission. 

(i) The term “Securities Act” means the Securities Act of 1933, as amended. 

In addition, for purposes of all calculations and notices under this Agreement, and all other provisions of this Agreement where the
context permits, a holder of Preferred Stock shall be deemed the Holder of the Registrable Shares issuable upon conversion thereof, and such Preferred Stock shall be deemed outstanding Registrable Shares hereunder. Notwithstanding the foregoing,
nothing in this Agreement shall require the Corporation actually to register any shares of Preferred Stock. 
 SECTION 2.
Request for Registration. If at any time after the earlier to occur of (i) the fourth anniversary of the date of the Original Agreement and (ii) the date six months after the closing of the first public offering of the
Corporation’s securities, the Corporation shall receive a written request (specifying that it is being made pursuant to this Section 2) from one or more Holders that hold, in the aggregate, at least one-third of the then outstanding
Registrable Shares, that the Corporation file a registration statement under the Securities Act, or a similar document pursuant to any other statute then in effect corresponding to the Securities Act, covering the

  
 2 

 
registration of at least the lesser of (a) at least one-third of the then outstanding Registrable Shares or (b) Registrable Shares the expected price to the public of which equals or
exceeds $5,000,000 (based on the market price or fair value on the date of such request), then the Corporation shall promptly notify all other Holders of such request and shall use its best efforts to cause all Registrable Shares that Holders have
requested be registered to be registered under the Securities Act on Form S-1 or any other available form the use of which is approved by the Holders of a majority of the Registrable Shares that are to be included in such registration. 

Notwithstanding the foregoing, (i) the Corporation shall not be obligated to effect a registration pursuant to this Section 2
during the period starting with the date sixty (60) days prior to the Corporation’s estimated date of filing of, and ending on a date six (6) months following the effective date of, a registration statement pertaining to an
underwritten public offering of securities for the account of the Corporation, provided that the Corporation is actively employing in good faith its best efforts to cause such registration statement to become effective and that the
Corporation’s estimate of the date of filing such registration statement is made in good faith; (ii) the Corporation shall not be obligated to effect more than two registrations pursuant to this Section 2; and (iii) if the
Corporation shall furnish to the Holders a certificate signed by the President of the Corporation stating that in the good faith judgment of the Board of Directors it would be seriously detrimental to the Corporation or its stockholders for a
registration statement to be filed in the near future, then the Corporation’s obligation to use its best efforts to file a registration statement shall be deferred for a period not to exceed ninety (90) days; provided,
however, that the Corporation shall not be permitted to so defer its obligation more than once in any 12-month period. 

SECTION 3. Corporation Registration. If at any time the Corporation proposes to register any of its Common Stock under the
Securities Act in connection with the public offering of such securities for its own account or for the accounts of stockholders other than Holders, solely for cash on a form that would also permit the registration of the Registrable Shares, the
Corporation shall, each such time, promptly give each Holder written notice of such determination. Upon the written request of any Holder given within thirty (30) days after giving of any such notice by the Corporation, the Corporation shall,
subject to the limitations set forth in Section 8, use its best efforts to cause to be registered under the Securities Act all of the Registrable Shares that each such Holder has requested be registered; provided, that the Corporation
shall have the right to postpone or withdraw any registration statement relating to an offering in which the Holders are eligible to participate under this Section 3 without any liability or obligation to the Holders under this Section 3.

 SECTION 4. Obligations of the Corporation. Whenever required under Section 2, Section 3 or Section 11
to use its best efforts to effect the registration of any Registrable Shares, the Corporation shall, as expeditiously as reasonably possible: 
 (a) Prepare and file with the SEC a registration statement with respect to such Registrable Shares and use its best efforts to cause such registration statement to become effective, and, upon the request
of the Holders of a majority of the Registrable Shares registered thereunder, keep such registration statement effective for a period of up to one hundred eighty (180) days or, if earlier, until the distribution contemplated in the registration
statement has been completed; provided, however, that (i) such 180-day period shall be extended for a period of time 

  
 3 

 
equal to the period the Holder refrains from selling any securities included in such registration at the request of an underwriter of Common Stock (or other securities) of the Corporation; and
(ii) in the case of any registration of Registrable Shares on Form S-3 which are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such 180-day period shall be extended for up to ninety
(90) days, if necessary, to keep the registration statement effective until all such Registrable Shares are sold. 
 (b)
Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect
to the disposition of all securities covered by such registration statement. 
 (c) Furnish to the selling Holders such numbers
of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of such Registrable Shares owned
by them. 
 (d) Use its best efforts to register and qualify the securities covered by such registration statement under such
other securities or Blue Sky laws of such jurisdictions as shall be reasonably appropriate for the distribution of the securities covered by the registration statement, provided that the Corporation shall not be required in connection therewith or
as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, and further provided that (anything in this Agreement to the contrary notwithstanding with respect to the
bearing of expenses) if any jurisdiction in which the securities shall be qualified shall require that expenses incurred in connection with the qualification of the securities in that jurisdiction be borne by selling stockholders, then such expenses
shall be payable by selling stockholders pro rata, to the extent required by such jurisdiction. 
 (e) Provide a transfer agent
for the Common Stock no later than the effective date of the first registration of any Registrable Shares. 
 (f) Otherwise use
its best efforts to comply with all applicable rules and regulations of the SEC. 
 (g) Use its best efforts to cause all such
Registrable Shares to be listed on a national securities exchange (if such securities are not already so listed) and on each additional national securities exchange on which similar securities issued by the Corporation are then listed, if the
listing of such securities is then permitted under the rules of such exchange. 
 (h) Enter into such customary agreements
(including an underwriting agreement in customary form) and take such other actions as the selling Holders of Registrable Shares shall reasonably request in order to expedite or facilitate the disposition of such Registrable Shares. 

(i) Make available for inspection by any selling Holder of Registrable Shares, by any underwriter participating in any disposition to be
effected pursuant to such registration statement and by any attorney, accountant or other agent retained by any such selling Holder or 

  
 4 

 
any such underwriter, all pertinent financial and other records and pertinent corporate documents and properties of the Corporation, and cause all of the Corporation’s officers, directors
and employees to supply all information reasonably requested by any such selling Holder, underwriter, attorney, accountant or agent in connection with such registration statement. 

(j) Use reasonable efforts to prevent the issuance of any stop order suspending the effectiveness of such registration statement or of
any order preventing or suspending the use of any preliminary prospectus and, if any such order is issued, to obtain the lifting thereof at the earliest reasonable time. 
 (k) Make such representations and warranties to the selling Holders of Registrable Shares and the underwriters as are customarily made by issuers to selling stockholders and underwriters, as the case may
be, in primary underwritten public offerings. 
 SECTION 5. Furnish Information. It shall be a condition precedent to the
obligations of the Corporation to take any action pursuant to this Agreement with respect to the registration of any Holder’s Registrable Shares that such Holder shall take such actions and furnish to the Corporation such information regarding
itself, the Registrable Shares held by it, and the intended method of disposition of such securities, as the Corporation shall reasonably request and as shall be required in connection with any registration, qualification or compliance referred to
in this Agreement, including, without limitation (i) in connection with an underwritten offering, enter into an appropriate underwriting agreement containing terms and provisions then customary in agreements of that nature, (ii) enter into
such custody agreements, powers of attorney and related documents at such time and on such terms and conditions as may then be customarily required in connection with such offering and (iii) distribute the Registrable Shares only in accordance
with and in the manner of the distribution contemplated by the applicable registration statement and prospectus. In addition, the Holders shall promptly notify the Corporation of any request by the SEC or any state securities commission or agency
for additional information or for such registration statement or prospectus to be amended or supplemented. 
 SECTION 6.
Expenses of Demand Registration. All expenses incurred in connection with any registration pursuant to Section 2 or Section 11 (excluding underwriters’ discounts and commissions), including, without limitation, all registration
and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Corporation, and the reasonable fees and disbursements of one special counsel for the selling Holders collectively, shall be borne by the
Corporation whether or not the registration statement to which such registration expenses relate becomes effective; provided, however, that the Corporation shall not be required to pay for any expenses of any registration proceeding
begun pursuant to Section 2 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Shares to be registered (in which case all participating Holders shall bear such expenses pro rata
based upon the number of Registrable Shares that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Shares agree to forfeit their right to one demand registration pursuant to Section 2;
provided further, however, that if at the time of such withdrawal, the Holders have learned of a material adverse change in the condition, business, or prospects of the Corporation from that known to the Holders at the time of their
request and have withdrawn the request with reasonable promptness after learning of such information, then the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to Section 2. 

  
 5 

 SECTION 7. Corporation Registration Expenses. All expenses (excluding
underwriters’ discounts and commissions) incurred in connection with any registration pursuant to Section 3, including, without limitation, any additional registration and qualification fees and any additional fees and disbursements of
counsel to the Corporation that result from the inclusion of securities held by the selling Holders in such registration and the reasonable fees and disbursements of one special counsel for the selling Holders collectively, shall be borne by the
Corporation whether or not the registration statement to which such registration expenses relate becomes effective. 
 SECTION
8. Underwriting Requirements. 
 (a) In connection with any offering under Section 3 involving an underwriting of
shares being issued by the Corporation, the Corporation shall not be required to include any Holder’s Registrable Shares in such underwriting unless such Holder accepts the terms of the underwriting as agreed upon between the Corporation and
the underwriters selected by it, and then only in such quantity as will not, in the reasonable opinion of the underwriters, jeopardize the success of the offering by the Corporation. If the total amount of securities that all Holders request to be
included in an underwritten offering under Section 3 exceeds the amount of securities that the underwriters reasonably believe compatible with the success of the offering, the Corporation may exclude some or all of the Registrable Shares from
such registration and underwriting, provided, however, that the number of Registrable Shares of the Holders to be included in such underwriting and registration shall not be reduced unless all other securities (excluding those of the
Corporation) are first entirely excluded from the underwriting and registration. If there is a reduction of the number of Registrable Shares pursuant to this Section 8(a), such reduction shall be made pro rata based upon the aggregate number of
Registrable Shares required to be registered by such Holders. 
 (b) With respect to any underwriting of shares to be registered
under Section 2 or Section 11, the selling Holders who initiate the request for registration shall have the right to designate the managing underwriter or underwriters, subject to the consent of the Corporation which shall not be
unreasonably withheld or delayed. In connection with any underwritings of shares to be registered under Section 3, the Corporation shall have the right to designate the managing underwriter or underwriters. 

SECTION 9. Delay of Registration. No Holder shall have any right to take any action to restrain, enjoin, or otherwise delay any
registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Agreement. 
 SECTION 10. Indemnification. In the event any Registrable Shares are included in a registration statement under this Agreement: 

(a) To the extent permitted by law, the Corporation will indemnify and hold harmless each Holder requesting or joining in a registration,
the partners, members, officers, directors and stockholders of such Holder, legal counsel and accountants for such Holder, any 

  
 6 

 
underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the 1934 Act, against
any losses, claims, damages or liabilities, joint or several, to which they may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based on
(i) any untrue or alleged untrue statement of any material fact contained in such registration statement, including, without limitation, any prospectus or final prospectus contained therein or any amendments or supplements thereto,
(ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading or (iii) any violation by the Corporation of any rule or regulation
promulgated under the Securities Act applicable to the Corporation and relating to action or inaction required of the Corporation in connection with any such registration; and will promptly reimburse each such Holder, underwriter, controlling person
or other aforementioned person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability, or action, provided, however, that the indemnity
agreement contained in this Section 10(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Corporation (which consent shall not be
unreasonably withheld or delayed) nor shall the Corporation be liable to any such Holder, underwriter, controlling person or other aforementioned person in any such case for any such loss, claim, damage, liability or action to the extent that it
(i) arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in connection with such registration statement, preliminary prospectus, final prospectus, or amendments or supplements
thereto, in reliance upon and in conformity with written information furnished to the Corporation expressly for use in connection with such registration by or on behalf of such Holder, underwriter, controlling person or other aforementioned person,
(ii) is caused by the failure of such Holder to deliver a copy of the final prospectus relating to such Registrable Shares, as then amended or supplemented, in connection with a purchase, if the Corporation had previously furnished copies
thereof to such Holder or (iii) is caused by such Holder’s disposition of Registrable Shares during any period during which such Holder is obligated to discontinue any disposition of Registrable Shares under Section 19. 

(b) To the extent permitted by law, each Holder requesting or joining in a registration, severally and not jointly, will indemnify and
hold harmless the Corporation, each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Corporation within the meaning of the Securities Act, and any underwriter (within the meaning
of the Securities Act) for the Corporation against any losses, claims, damages or liabilities to which the Corporation or any such director, officer, controlling person or underwriter may become subject, under the Securities Act or otherwise,
insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon (i) any untrue statement or alleged untrue statement of any material fact contained in such registration statement, including
any prospectus or final prospectus contained therein or any amendments or supplements thereto or (ii) the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein
not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in reliance upon and in conformity with written information relating to and furnished
to the Corporation by such Holder expressly for use in connection with such registration; and will promptly reimburse the Corporation or any such 

  
 7 

 
director, officer, controlling person or underwriter for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage,
liability or action; provided, however, that the indemnity agreement contained in this Section 10(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected
without the consent of such Holder (which consent shall not be unreasonably withheld or delayed) and provided further that no Holder shall have any liability under this Section 10(b) in excess of the net proceeds actually received by such
Holder in the relevant public offering. 
 (c) Promptly after receipt by an indemnified party under this Section 10 of
notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 10, notify the indemnifying party in writing of the commencement thereof and
the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the
parties. The failure to notify an indemnifying party promptly of the commencement of any such action, if prejudicial to his ability to defend such action, shall relieve such indemnifying party of any liability to the indemnified party under this
Section 10 to the extent the indemnifying party is prejudiced by a delay of such notification, but the omission so to notify the indemnifying party will not relieve him of any liability that he may have to any indemnified party otherwise than
under this Section 10. 
 (d) If the indemnification provided for in this Section 10 is required by its terms but is
for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party under Section 10(a) or Section 10(b) in respect of any losses, claims, damages, liabilities or expenses referred to herein, then each
applicable indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of any losses, claims, damages, liabilities or expenses referred to herein in such proportion as is appropriate to reflect the
relative fault of the Corporation and the selling Holders in connection with the statements or omissions described in such Section 10(a) or Section 10(b) which resulted in such losses, claims, damages, liabilities or expenses, as well as
any other relevant equitable considerations. The relative fault of the Corporation and the selling Holders shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or
alleged omission to state a material fact relates to information supplied by the Corporation or the selling Holders and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or
omission. The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in this Section 10, any legal or other fees
or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions set forth in Section 10(c) with respect to notice of commencement of any action shall apply if a claim for
contribution is to be made under this Section 10(d); provided, however, that no additional notice shall be required with respect to any action for which notice has been given under subsection Section 10(c) for purposes of
indemnification. The Corporation and the selling Holders agree that it would not be just and equitable if contribution pursuant to this Section 10 were determined solely by pro rata allocation or by any other method of allocation which does not
take account of the equitable considerations referred to in this paragraph. Notwithstanding the provisions of this Section 10(d), 

  
 8 

 
no Holder shall be required to contribute an amount in excess of the net proceeds actually received by such Holder in the relevant public offering. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. 

(e) The rights and obligations of the Corporation and the Holders under this Section 10 shall survive termination of this Agreement.

 SECTION 11. Registrations on Form S-3. 
 (a) If (i) the Corporation shall receive a written request (specifying that it is being made pursuant to this Section 11) from one or more Holders that the Corporation file a registration
statement on Form S-3 (or any successor form to Form S-3 regardless of its designation) for a public offering of Registrable Shares the reasonably anticipated aggregate price to the public of which would equal or exceed $ 1,000,000, and
(ii) the Corporation is a registrant entitled to use Form S-3 (or any successor form to Form S-3) to register such shares, then the Corporation shall promptly notify all other Holders of such request and shall use its best efforts to cause all
Registrable Shares that Holders have requested be registered to be registered on Form S-3 (or any successor form to Form S-3). 

(b) Notwithstanding the foregoing, (i) the Corporation shall not be obligated to effect a registration pursuant to this
Section 11 during the period starting with the date sixty (60) days prior to the Corporation’s estimated date of filing of, and ending on a date six (6) months following the effective date of, a registration statement pertaining
to an underwritten public offering of securities for the account of the Corporation, provided that the Corporation is actively employing in good faith its best efforts to cause such registration statement to become effective and that the
Corporation’s estimate of the date of filing such registration statement is made in good faith; (ii) the Corporation shall not be obligated to effect more than four registrations pursuant to this Section 11; and (iii) if the
Corporation shall furnish to the Holders a certificate signed by the President of the Corporation stating that in the good faith judgment of the Board of Directors it would be seriously detrimental to the Corporation or its stockholders for a
registration statement to be filed in the near future, then the Corporation’s obligation to use its best efforts to file a registration statement shall be deferred for a period not to exceed ninety (90) days; provided,
however, that the Corporation shall not be permitted to so defer its obligation more than once in any 12-month period. 

(c) The Holders’ rights to registration under this Section 11 are in addition to, and not in lieu of, their rights to
registration under Section 2 and Section 3 of this Agreement. 
 SECTION 12. Limitation on Corporation
Offerings. The Corporation shall not register securities for sale for its own account (or, except as permitted by Section 14, any securities other than Registrable Shares) in any registration requested pursuant to Section 2 or
Section 11 unless permitted to do so by the written consent of the Holders of a majority of the Registrable Shares as to which registration has been requested unless the inclusion of securities for the account of the Corporation would not
require a reduction in the number of Registrable Shares to be included in such registration, as determined by the managing underwriter. 

  
 9 

 SECTION 13. Reports Under Securities Exchange Act of 1934. With a view to making
available to the Holders the benefits of Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Corporation to the public without registration, the Corporation agrees to use its best
efforts to: 
 (a) make and keep public information available, as those terms are understood and used in Rule 144, at all times
subsequent to ninety (90) days after the effective date of the first registration statement covering an underwritten public offering filed by the Corporation; 
 (b) file with the SEC in a timely manner all reports and other documents, if any, required of the Corporation under the Securities Act and the 1934 Act; and 

(c) furnish to any Holder forthwith upon request (at any time after ninety (90) days after the effective date of said first
registration statement filed by the Corporation) a written statement by the Corporation that it has complied with the reporting requirements of the 1934 Act for the 12 months preceding the date of such request, a copy of the most recent publicly
filed annual or quarterly report of the Corporation, and such other reports and documents so filed by the Corporation as may be reasonably requested in availing any such Holder to take advantage of any rule or regulation of the SEC permitting the
selling of any such securities without registration. 
 SECTION 14. Limitations in Connection with Future Grants of
Registration Rights. Without the prior written consent of the Holders of at least 60% in voting power of then outstanding Registrable Shares held by Investors, the Corporation shall not grant rights to any person or entity: (a) to cause the
Corporation to register any of such person’s or entity’s securities of the Corporation; (b) to include such person’s or entity’s securities of the Corporation in any registration statement filed under Section 2 or
Section 11 hereof; (c) to include such person’s or entity’s securities of the Corporation in any registration statement described in Section 3 hereof, unless, in the case of each of (a), (b) and (c), under the terms of
such agreement, such person or entity may include such securities in any such registration only to the extent that the inclusion of his or its securities will not reduce the amount of Registrable Shares of the Holders which is included in such
registration; or (d) otherwise to cause the registration of such person’s or entity’s securities of the Corporation in any manner which are superior to or pari passu with the registration rights granted herein to the Holders.

 SECTION 15. Transfer of Registration Rights. The registration rights and obligations of any Holder (and of any
transferee of any Holder, or its transferees, of the rights under this Agreement in accordance with this Section 15) under this Agreement with respect to any Registrable Shares may be transferred to any transferee who acquires (otherwise than
in a registered public offering) at least five percent (5%) of the Registrable Shares then held by such Holder; provided, however, that the transfer of registration rights to any Affiliate of any Holder will not be subject to such
requirement as to minimum shareholding; provided, further, that (a) such rights and obligations may not be transferred to any entity whose primary line of business is directly competitive with the primary line of business of the
Corporation, as determined in good faith by the Board of Directors, (b) the Corporation shall be given written notice by the Holder at the time of any permitted transfer stating the name and address of the transferee and identifying the
securities with respect to which the rights and obligations under this Agreement are being assigned and (c) the transferee shall execute an agreement to be bound by the terms of this Agreement. 

  
 10 

 SECTION 16. Termination of Registration Rights. All of the Corporation’s
obligations to register Registrable Shares under Sections 2, 3 and 11 hereof shall terminate upon the earliest of (a) five years after the closing of the Initial Public Offering, (b) the date on which no Purchaser holds any Registrable
Shares or (c) a Company Sale (as defined below). 
 SECTION 17. Mergers, Etc. The Corporation shall not, directly or
indirectly, enter into any merger, consolidation or reorganization in which the Corporation shall not be the surviving corporation unless the proposed surviving corporation shall, prior to such merger, consolidation or reorganization, agree in
writing to assume the obligations of the Corporation under this Agreement, and for that purpose references hereunder to “Registrable Shares” shall be deemed to be references to the securities which the Holders would be entitled to receive
in exchange for Registrable Shares under any such merger, consolidation or reorganization; provided, however, that the provisions of this Agreement shall not apply in the event of any merger, consolidation or reorganization in which
the Corporation is not the surviving corporation if the Holders of Registrable Shares are entitled to receive in exchange therefor (i) cash, or (ii) securities of the acquiring corporation which may be immediately sold to the public
without registration under the Securities Act (a “Company Sale”). 
 SECTION 18. Stand-Off Agreement. In
connection with the initial public offering of the Corporation’s securities pursuant to a registration statement under the Securities Act, each Holder, if requested by the Corporation and the managing underwriter of such offering by the
Corporation, shall agree, by executing and delivering such form of agreement as the Corporation and such underwriter shall reasonably request, not to sell publicly or otherwise transfer or dispose of any Registrable Shares or other securities of the
Corporation held by such Holder prior to the effective date of such registration statement for a specified period of time immediately following the effective date of such registration statement, such period of time not to exceed one hundred eighty
(180) days; provided that: 
 (a) such one-hundred eighty (180) day period may be extended on one occasion by
the managing underwriter to the extent necessary to prevent the managing underwriter(s) from violating Section 2711(f)(4) of the rules of the National Association of Securities Dealers, Inc., as incorporated into the rules of the Financial
Industry Regulatory Authority, or any similar successor provision (e.g., as the result of the publication or other distribution of a research report or public appearance concerning the Company); 

(b) such agreement shall not apply to resales of the Corporation’s securities purchased by a Holder in a public market, and

 (c) all persons who hold shares of Common Stock, or securities convertible into or exchangeable or exercisable for shares of
Common Stock, which in aggregate represent one percent (1%) or more of the shares of Common Stock then outstanding (including all securities convertible into or exchangeable or exercisable for shares of Common Stock, on an as converted,
exchanged or exercised basis), and all officers and directors of the Corporation, enter into similar agreements. 

  
 11 

 Notwithstanding the foregoing, any discretionary waiver by an underwriter of a lock-up agreement shall not
be effective unless such underwriter also releases all other stockholders of the Corporation from the equivalent provisions and a pro rata portion of their respective lock-up agreements. 

SECTION 19. Future Events. The Corporation will notify each Holder participating in a registration of the occurrence of any of the
following events of which the Corporation is actually aware, and when so notified, each Holder will immediately discontinue any disposition of Registrable Shares until notified by the Corporation that such event is no longer applicable: 

(a) the issuance by the SEC or any state securities commission or agency of any stop order suspending the effectiveness of the
registration statement or the initiation of any proceedings for that purpose (in which case the Corporation will make reasonable efforts to obtain the withdrawal of any such order or the cessation of any such proceedings); or 

(b) the existence of any fact which makes untrue any material statement made in the registration statement or prospectus or any document
incorporated therein by reference or which requires the making of any changes in the registration statement or prospectus or any document incorporated therein by reference in order to make the statements therein not misleading (in which case the
Corporation will make reasonable efforts to amend the applicable document to correct the deficiency). 
 SECTION 20.
Notices. All notices, requests, consents and other communications hereunder (“Notices”) to any party shall be contained in a written instrument addressed to such party at the address set forth below or such other address as
may hereafter be designated in writing by the addressee to the addressor listing all parties and shall be deemed given (a) when delivered in person or duly sent by fax showing confirmation of receipt, (b) three days after being duly sent
by first class mail postage prepaid (other than in the case of Notices to or from any non-U.S. resident, which Notices must be sent in the manner specified in clause (a) or (c)), or (c) two days after being duly sent by recognized express
international courier service: 
 if to the Corporation, to: 

Concert Pharmaceuticals, Inc. 
 99 Hayden Avenue, Suite 500 
 Lexington, MA 02421 

Fax: (781) 860-8923 
 with a copy to: 
 David E. Redlick 

Lia Der Marderosian 
 Wilmer Cutler Pickering Hale and Dorr LLP 
 60 State Street 

Boston, MA 02109 

Fax: (617) 526-5000 

  
 12 

 if to the Investors, to their respective addresses set forth on signature pages to this
Agreement, with a copy to: 
 H. David Henken 
 Goodwin Proctor LLP 
 Exchange Place 

53 State Street 

Boston, MA 02109 

Fax: (617) 523-1231 
 SECTION 21. Miscellaneous. 
 (a) This Agreement states the entire agreement
of the parties concerning the subject matter hereof, and supersedes all prior agreements, written or oral, between or among them concerning such subject matter. Upon the effectiveness of this Agreement, the Original Agreement shall be deemed amended
and restated and superseded and replaced in its entirety by this Agreement, and shall be of no further force or effect. 
 (b)
This Agreement may be amended, and compliance with any provision of this Agreement may be omitted or waived, only by the written agreement of the Corporation and the Holders of at least sixty percent (60%) of the Series B Preferred Stock,
Series C Preferred Stock, Series D Preferred Stock and Common Stock issued upon conversion of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock (voting together as a single class on an as converted to Common Stock
basis) then in voting power; provided however that no amendment or waiver may treat one Investor or group of Investors more adversely than any other Investor or group of Investors without the consent of such Investor or the consent of the
Holders of a majority in voting power of the then outstanding Registrable Shares held by the Investor or group of Investors adversely affected by such amendment or waiver. 
 (c) This Agreement shall be governed by, and construed and enforced in accordance with, the substantive laws of the Commonwealth of Massachusetts, without regard to its principles of conflicts of laws.

 (d) This Agreement may be executed in any number of counterparts, each such counterpart shall be deemed to be an original
instrument, and all such counterparts together shall constitute but one agreement. Any such counterpart may contain one or more signature pages. This Agreement may be executed by facsimile signature pages. 

SECTION 22. Aggregation of Stock. All shares of Preferred Stock and Common Stock of the Corporation held or acquired by Affiliates
of a Holder shall be aggregated for the purpose of determining the availability of any rights under this Agreement. 
 [
Signature Pages Follow ] 

  
 13 

 IN WITNESS WHEREOF, the parties have executed this Third Amended and Restated Registration
Rights Agreement as a contract under seal as of the date first written above. 
 THE CORPORATION: 

 

			
	CONCERT PHARMACEUTICALS, INC.
		
	By:	 	/s/ Roger D. Tung
		 	  

	Name:	 	Roger D. Tung
	Title:	 	Chief Executive Officer

 [ Company Signature Page to Concert Pharmaceuticals, Inc. Third Amended and Restated Registration
Rights Agreement ] 

 By executing this page in the space provided, the undersigned hereby agree (i) that
each is an “Investor” as defined in the Third Amended and Restated Registration Rights Agreement dated as of the date first above written, by and among Concert Pharmaceuticals, Inc. and the parties named therein (the
“Registration Rights Agreement”), (ii) that each is a party to the Registration Rights Agreement for all purposes and (iii) that each is bound by all terms and conditions of the Registration Rights Agreement. 

EXECUTED this 1st day of June, 2009. 
 THE PURCHASING INVESTOR: 
  

					
	GLAXO GROUP LIMITED
		
	By:	 	/s/ Paul Williamson
		 	  

		 	Name:	 	
		 	Title:	 	 Paul Williamson
 For and on
behalf of
 Edinburgh Pharmaceutical Industries Limited
 Corporate Director

 [ Investor Signature Page to Concert Pharmaceuticals, Inc. Third Amended and Restated Registration
Rights Agreement ] 

 By executing this page in the space provided, the undersigned hereby agree (i) that
each is an “Investor” as defined in the Third Amended and Restated Registration Rights Agreement dated as of the date first above written, by and among Concert Pharmaceuticals, Inc. and the parties named therein (the
“Registration Rights Agreement”), (ii) that each is a party to the Registration Rights Agreement for all purposes and (iii) that each is bound by all terms and conditions of the Registration Rights Agreement. 

EXECUTED this      day of
                    , 2009. 
 THE INVESTOR:

  

			
	FIDELITY MT. VERNON STREET TRUST: FIDELITY GROWTH COMPANY FUND
		
	By:	 	  

		 	Name:
		 	Title:

  

									
		 		 	To such Investor at:
				
		 		 	Address:	 	 82 Devonshire Street, V13H
		 		 		 	 Boston, MA 02109
		 		 		 	 Attn:	 	 Andrew J. Boyd,
		 		 		 		 	 Associate General Counsel
		 		 	Fax:	 	 (617) 392-1605

 [ Investor Signature Page to Concert Pharmaceuticals, Inc. Third Amended and Restated Registration
Rights Agreement ] 

 By executing this page in the space provided, the undersigned hereby agree (i) that
each is an “Investor” as defined in the Third Amended and Restated Registration Rights Agreement dated as of the date first above written, by and among Concert Pharmaceuticals, Inc. and the parties named therein (the
“Registration Rights Agreement”), (ii) that each is a party to the Registration Rights Agreement for all purposes and (iii) that each is bound by all terms and conditions of the Registration Rights Agreement. 

EXECUTED this      day of             , 2009. 

THE INVESTORS: 
  

					
	WESTFIELD LIFE SCIENCES FUND LP
		
	By:	 	  

		 	Name:	 	William A. Muggia
		 	Title:	 	Director
	
	WESTFIELD LIFE SCIENCES FUND II LP
		
	By:	 	  

		 	Name: 	 	William A. Muggia
		 	Title:	 	Director

  

									
		 		 	To each such Investor at:
				
		 		 	Address:	 	  Westfield Capital Management
  One Financial Center, 24th Floor

		 		 		 	 Boston, MA 02111
		 		 		 	 Attn: 	 	Eric D. Changelian,
		 		 		 		 	Manager of Fund Operations
		 		 	Fax:	 	 (617) 867-2801

 [ Investor Signature Page to Concert Pharmaceuticals, Inc. Third Amended and Restated Registration
Rights Agreement ] 

 By executing this page in the space provided, the undersigned hereby agree (i) that
each is an “Investor” as defined in the Third Amended and Restated Registration Rights Agreement dated as of the date first above written, by and among Concert Pharmaceuticals, Inc. and the parties named therein (the
“Registration Rights Agreement”), (ii) that each is a party to the Registration Rights Agreement for all purposes and (iii) that each is bound by all terms and conditions of the Registration Rights Agreement. 

EXECUTED this 1st day of June, 2009. 
 THE INVESTOR: 
  

					
	ADAGE CAPITAL PARTNERS, L.P.
		
	By:	 	/s/ Dan Lehan
		 	  

		 	Name:	 	Dan Lehan
		 	Title:	 	Chief Operating Officer

  

							
		 		 	To such Investor at:
				
		 		 	Address: 	 	200 Clarendon St., 52nd Floor
		 		 		 	Boston, MA 02116
		 		 	Fax:	 	(617) 867-2801

 [ Investor Signature Page to Concert Pharmaceuticals, Inc. Third Amended and Restated Registration
Rights Agreement ] 

 By executing this page in the space provided, the undersigned hereby agree (i) that
each is an “Investor” as defined in the Third Amended and Restated Registration Rights Agreement dated as of the date first above written, by and among Concert Pharmaceuticals, Inc. and the parties named therein, (the
“Registration Rights Agreement”), (ii) that each is a party to the Registration Rights Agreement for all purposes and (iii) that each is bound by all terms and conditions of the Registration Rights Agreement. 

EXECUTED this 1st day of June, 2009. 
 THE INVESTORS: 
  

													
	 MEDIPHASE VENTURE PARTNERS II
 LIMITED PARTNERSHIP
	 		 	 MEDIPHASE VENTURE PARTNERS
 (DP & UP) LIMITED PARTNERSHIP

					
	By:	 	Mediphase II LLC	 		 	By:	 	Mediphase (DP&UP) LLC
	Its:	 	General Partner	 		 	Its:	 	General Partner
					
	By:	 	/s/ Paul A. Howard	 		 	By:	 	/s/ Paul A. Howard
		 	  
	 		 		 	  

		 	Name:	 	Paul A. Howard	 		 		 	Name:	 	Paul A. Howard
		 	Title:	 	Manager	 		 		 	Title:	 	Manager

  

																	
	MEDIPHASE VENTURE PARTNERS II	 		 		 		 	To each such Investor at:
	 (ANNEX FUND) LIMITED
 PARTNERSHIP
	 		 		 		 	Address:	 	Mediphase Venture Partners
		 		 		 		 		 	3 Newton Executive Park
	By:	 	Mediphase II (Annex Fund) LLC	 		 		 		 		 	2223 Washington Street
	Its:	 	General Partner	 		 		 		 		 	 Suite 104
 Newton,
MA 02462

	By:	 	/s/ Paul A. Howard	 		 		 		 		 	Attn:	 	 Amanda Cobb,
 Operations
Manager

	 	 		 		 		 	Fax:	 	(617) 332-8463
		 	  
	 		 		 		 		 	
		 	Name:	 	Paul A. Howard	 		 		 		 		 	
		 	Title:	 	Manager	 		 		 		 		 		 	

 [ Investor Signature Page to Concert Pharmaceuticals, Inc. Third Amended and Restated Registration Rights
Agreement ] 

 By executing this page in the space provided, the undersigned hereby agree (i) that
each is an “Investor” as defined in the Third Amended and Restated Registration Rights Agreement dated as of the date first above written, by and among Concert Pharmaceuticals, Inc. and the parties named therein (the
“Registration Rights Agreement”), (ii) that each is a party to the Registration Rights Agreement for all purposes and (iii) that each is bound by all terms and conditions of the Registration Rights Agreement. 

EXECUTED this 1st day of June, 2009. 
 THE INVESTOR: 
  

					
	S.R. ONE, LIMITED
		
	By:	 	/s/ Carol G. Ashe
		 	  

		 	Name:	 	Carol G. Ashe
		 	Title:	 	Partner/Vice President

  

									
		 		 	To such Investor at:
				
		 		 	Address:	 	  161 Washington Street
  Suite 500
  Eight Tower Bridge

		 		 		 	 Conshohocken, PA 19428
		 		 		 	 Attn:	 	   Rajeev Dadoo, Ph.D.
		 		 	Fax:	 	 (610) 567-1039

 [ Investor Signature Page to Concert Pharmaceuticals, Inc. Third Amended and Restated Registration
Rights Agreement ] 

 By executing this page in the space provided, the undersigned hereby agree (i) that
each is an “Investor” as defined in the Third Amended and Restated Registration Rights Agreement dated as of the date first above written, by and among Concert Pharmaceuticals, Inc. and the parties named therein (the
“Registration Rights Agreement”), (ii) that each is a party to the Registration Rights Agreement for all purposes and (iii) that each is bound by all terms and conditions of the Registration Rights Agreement. 

EXECUTED this 1st day of June, 2009. 
 THE INVESTORS: 
  

													
	THREE ARCH PARTNERS IV, L.P.	 		 	THREE ARCH PARTNERS III, L.P.
					
	By:	 	Three Arch Management IV, L.L.C.	 		 	By:	 	Three Arch Management III, L.L.C.
	Its:	 	General Partner	 		 	Its:	 	General Partner
					
	By:	 	/s/ Wilfred Jaeger	 		 	By:	 	/s/ Wilfred Jaeger
		 	  
	 		 		 	  

	Name:	 	Wilfred Jaeger	 		 	Name:	 	Wilfred Jaeger
	Title:	 	Managing Member	 		 	Title:	 	Managing Member

  

													
	THREE ARCH ASSOCIATES IV, L.P.	 		 	THREE ARCH ASSOCIATES III, L.P.
					
	By:	 	Three Arch Management IV, L.L.C.	 		 	By:	 	Three Arch Management III, L.L.C.
	Its:	 	General Partner	 		 	Its:	 	General Partner
					
	By:	 	/s/ Wilfred Jaeger	 		 	By:	 	/s/ Wilfred Jaeger
		 	  
	 		 		 	  

	Name:	 	Wilfred Jaeger	 		 	Name:	 	Wilfred Jaeger
	Title:	 	Managing Member	 		 	Title:	 	Managing Member

  

																	
		 		 		 		 		 	To each such Investor at:
							
		 		 		 		 		 	Address:	 	  3200 Alpine Road
  Portola Valley, CA 94028

		 		 		 		 		 		 		 	 Attn:	 	Steve Bonelli,
		 		 		 		 		 		 		 		 	Chief Financial Officer
		 		 		 		 		 	Fax:	 	 (650) 529-8039

 [ Investor Signature Page to Concert Pharmaceuticals, Inc. Third Amended and Restated Registration Rights
Agreement ] 

 By executing this page in the space provided, the undersigned hereby agree (i) that
each is an “Investor” as defined in the Third Amended and Restated Registration Rights Agreement dated as of the date first above written, by and among Concert Pharmaceuticals, Inc. and the parties named therein (the
“Registration Rights Agreement”), (ii) that each is a party to the Registration Rights Agreement for all purposes and (iii) that each is bound by all terms and conditions of the Registration Rights Agreement. 

EXECUTED this      day of             , 2009. 

THE INVESTORS: 
  

					
	GREYLOCK XII LIMITED PARTNERSHIP
		
	By:	 	Greylock XII GP LLC, its General Partner
		
	By:	 	  

		 	Name:	 	Donald A. Sullivan
		 	Title:	 	Administrative Partner
	
	GREYLOCK XII-A LIMITED PARTNERSHIP
		
	By:	 	Greylock XII GP LLC, its General Partner
		
	By:	 	  

		 	Name:	 	Donald A. Sullivan
		 	Title:	 	Administrative Partner
	
	GREYLOCK XII PRINCIPALS LLC
		
	By:	 	Greylock Management Corporation, Sole Member
		
	By:	 	  

		 	Name:	 	Donald A. Sullivan
		 	Title:	 	Treasurer

  

									
		 		 	To each such Investor at:
				
		 		 	Address:	 	 880 Winter Street
		 		 		 	 Waltham, MA 02451
		 		 		 	 Attn:	 	 Donald A. Sullivan,
		 		 		 		 	 Treasurer
		 		 	Fax:	 	 (781) 622-2326

 [ Investor Signature Page to Concert Pharmaceuticals, Inc. Third Amended and Restated Registration
Rights Agreement ] 

 By executing this page in the space provided, the undersigned hereby agree (i) that
each is an “Investor” as defined in the Third Amended and Restated Registration Rights Agreement dated as of the date first above written, by and among Concert Pharmaceuticals, Inc. and the parties named therein (the
“Registration Rights Agreement”), (ii) that each is a party to the Registration Rights Agreement for all purposes and (iii) that each is bound by all terms and conditions of the Registration Rights Agreement. 

EXECUTED this 1st day of June, 2009. 
 THE INVESTORS: 
  

					
	TVM LIFE SCIENCE VENTURES VI GMBH & CO. KG
		
		 	/s/ Jens Eckstein
		 	  

		 	By:	 	Jens Eckstein
		 	Its:	 	Managing Limited Partner
		
		 	/s/ David Poltack
		 	  

		 	By:	 	David Poltack
		 	Its:	 	Managing Limited Partner
	
	TVM LIFE SCIENCE VENTURES VI LP
	
	 By: TVM Life Science Ventures VI Cayman Ltd.,
 Its General Partner

		
		 	/s/ Jens Eckstein
		 	  

		 	By:	 	Jens Eckstein
		 	Its:	 	Authorized Officer
		
		 	/s/ David Poltack
		 	  

		 	By:	 	David Poltack
		 	Its:	 	Authorized Officer

  

									
		 		 	To each such Investor at:
				
		 		 	Address:	 	 101 Arch Street, Suite 1950
		 		 		 	 Boston, MA 02110
		 		 		 	 Attn:	 	 David Poltack
		 		 	Fax:	 	 (617) 345-9377

 [ Investor Signature Page to Concert Pharmaceuticals, Inc. Third Amended and Restated Registration
Rights Agreement ] 

 By executing this page in the space provided, the undersigned hereby agree (i) that
each is an “Investor” as defined in the Third Amended and Restated Registration Rights Agreement dated as of the date first above written, by and among Concert Pharmaceuticals, Inc. and the parties named therein (the
“Registration Rights Agreement”), (ii) that each is a party to the Registration Rights Agreement for all purposes and (iii) that each is bound by all terms and conditions of the Registration Rights Agreement. 

EXECUTED this 1st day of June, 2009. 
 THE INVESTOR: 
  

					
	SKYLINE VENTURE PARTNERS
	QUALIFIED PURCHASER FUND IV, L.P.
		
	By:	 	Skyline Venture Management IV, LLC
	Its:	 	General Partner
		
	By:	 	/s/ John Freund
		 	  

		 	Name:	 	John Freund
		 	Title:	 	Managing Director

  

									
		 		 	To such Investor at:
				
		 		 	Address:	 	 c/o Skyline Ventures
		 		 		 	  525 University Avenue
  Suite 520
  Palo Alto, CA 94301

		 		 		 	 Attn:	 	 Kerry Kenny
		 		 	Fax:	 	 (650) 329-1090

 [ Investor Signature Page to Concert Pharmaceuticals, Inc. Third Amended and Restated Registration
Rights Agreement ] 

 By executing this page in the space provided, the undersigned hereby agree (i) that
each is an “Investor” as defined in the Third Amended and Restated Registration Rights Agreement dated as of the date first above written, by and among Concert Pharmaceuticals, Inc. and the parties named therein (the
“Registration Rights Agreement”), (ii) that each is a party to the Registration Rights Agreement for all purposes and (iii) that each is bound by all terms and conditions of the Registration Rights Agreement. 

EXECUTED this 1st day of June, 2009. 
 THE INVESTOR: 
  

					
	QVT FUND LP
		
	By:	 	QVT Associates GP LLC
	Its:	 	General Partner
		
	By:	 	/s/ Tracy Fu
		 	  

		 	Name:	 	Tracy Fu
		 	Title:	 	Managing Member
		
	By:	 	/s/ Keith S Manchester
		 	  

		 	Name:	 	 Keith S Manchester

		 	Title:	 	 Portfolio Manager

  

									
		 		 	To such Investor at:
				
		 		 	Address:	 	 c/o QVT Financial LP
		 		 		 	  1177 Avenue of the Americas
  9th
Floor
  New York, NY 10036

		 		 		 	 Attn:	 	 Keith Manchester
		 		 	Fax:	 	 (212) 705-8820
			
		 		 	Note: Registered Address is:
				
		 		 	Address:	 	 c/o Walkers SPV
		 		 		 	  Walker House

 P.O. Box 908GT, Mary Street
  George
Town, Grand Cayman
  Cayman Islands

 [ Investor Signature Page to Concert Pharmaceuticals, Inc. Third Amended and Restated Registration
Rights Agreement ] 

 By executing this page in the space provided, the undersigned hereby agree (i) that
each is an “Investor” as defined in the Third Amended and Restated Registration Rights Agreement dated as of the date first above written, by and among Concert Pharmaceuticals, Inc. and the parties named therein (the
“Registration Rights Agreement”), (ii) that each is a party to the Registration Rights Agreement for all purposes and (iii) that each is bound by all terms and conditions of the Registration Rights Agreement. 

EXECUTED this 1st day of June, 2009. 
 THE INVESTOR: 
  

					
	FLAGSHIP VENTURES FUND 2004, L.P.
		
	By:	 	Flagship Ventures General Partner, LLC
		 	its General Partner
		
	By:	 	/s/ Noubar Afeyan
		 	  

		 	Name:	 	Noubar Afeyan
		 	Title:	 	

  

									
		 		 	To such Investor at:
				
		 		 	Address:	 	 One Memorial Drive
		 		 		 	 7th Floor
		 		 		 	 Cambridge, MA 02142
		 		 		 	 Attn:	 	 Douglas G. Cole, M.D.
		 		 	Fax:	 	 (617) 868-1115

 [ Investor Signature Page to Concert Pharmaceuticals, Inc. Third Amended and Restated Registration
Rights Agreement ] 

 By executing this page in the space provided, the undersigned hereby agree (i) that
each is an “Investor” as defined in the Third Amended and Restated Registration Rights Agreement dated as of the date first above written, by and among Concert Pharmaceuticals, Inc. and the parties named therein (the
“Registration Rights Agreement”), (ii) that each is a party to the Registration Rights Agreement for all purposes and (iii) that each is bound by all terms and conditions of the Registration Rights Agreement. 

EXECUTED this 1st day of June, 2009. 
 THE INVESTOR: 
  

					
	BROOKSIDE CAPITAL PARTNERS FUND, LP
		
	By:	 	/s/ Matt McPherron
		 	  

		 	Name:	 	Matt McPherron
		 	Title:	 	Managing Director

  

									
		 		 	To such Investor at:
				
		 		 	Address:	 	 c/o Bain Capital
		 		 		 	  111 Huntington Avenue
  Boston, MA 02199

		 		 		 	 Attn:	 	  Marlene Wojcik,

 Chief Financial Officer

		 		 	Fax:	 	 (617) 516-2910

 [ Investor Signature Page to Concert Pharmaceuticals, Inc. Third Amended and Restated Registration
Rights Agreement ] 

 By executing this page in the space provided, the undersigned hereby agree (i) that
each is an “Investor” as defined in the Third Amended and Restated Registration Rights Agreement dated as of the date first above written, by and among Concert Pharmaceuticals, Inc. and the parties named therein (the
“Registration Rights Agreement”), (ii) that each is a party to the Registration Rights Agreement for all purposes and (iii) that each is bound by all terms and conditions of the Registration Rights Agreement. 

EXECUTED this 1st day of June, 2009. 
 THE INVESTOR: 
  

									
	New Leaf Ventures I, L.P.
			
		 	By:	 	New Leaf Venture Management I, L.P.
		 	Its:	 	General Partner
				
		 		 	By:	 	New Leaf Venture Management I, L.L.C.
		 		 	Its:	 	General Partner
				
		 		 		 	/s/ Vijay K. Lathi
		 		 		 	  

		 		 		 	By:	 	Vijay K. Lathi
		 		 		 	Its:	 	Managing Director

  

									
		 		 	To such Investor at:
				
		 		 	Address:	 	 2500 Sand Hill Road
		 		 		 	  Suite 203

 Menlo Park, CA 94025

		 		 		 	 Attn:	 	 Craig L. Slutzkin,
		 		 		 		 	 Chief Financial Officer
		 		 	Fax:	 	 (650) 234-2704

 [ Investor Signature Page to Concert Pharmaceuticals, Inc. Third Amended and Restated Registration
Rights Agreement ] 

 By executing this page in the space provided, the undersigned hereby agree (i) that
each is an “Investor” as defined in the Third Amended and Restated Registration Rights Agreement dated as of the date first above written, by and among Concert Pharmaceuticals, Inc. and the parties named therein (the
“Registration Rights Agreement”), (ii) that each is a party to the Registration Rights Agreement for all purposes and (iii) that each is bound by all terms and conditions of the Registration Rights Agreement. 

EXECUTED this 1st day of June, 2009. 
 THE INVESTORS: 
  

											
		 		 		 	  

		 		 		 	Name:  Peter Kolchinsky
				
		 		 		 	  

		 		 		 	Name:  Caleb Aldrich
				
		 		 		 	/s/ Peter Barton Hutt
		 		 		 	  

		 		 		 	Name:  Peter Barton Hutt
			
		 		 	RA CAPITAL ASSOCIATES, INC.
				
		 		 		 	  

		 		 		 	By:     Richard H. Aldrich
		 		 		 	Title:  Managing Director
				
		 		 		 	To such Investor at:
				
		 		 		 	Address:  800 Boylston Street, Suite 1500
		 		 		 	       Boston, MA 02199

			
		 		 	TUNG FAMILY INVESTMENT TRUST
					
		 		 		 	By:	 	
		 		 		 		 	  

		 		 		 		 	Name:  Roger D. Tung
		 		 		 		 	Title:    Trustee
					
		 		 		 		 	 To each such Investor,
 care of the Corporation:

						
		 		 		 		 	Address:	 	 99 Hayden Avenue
		 		 		 		 		 	  Suite 100

 Lexington, MA

		 		 		 		 	Fax:	 	 (781) 860-8923

 [ Investor Signature Page to Concert Pharmaceuticals, Inc. Third Amended and Restated Registration Rights
Agreement ] 

 By executing this page in the space provided, the undersigned hereby agree (i) that
each is an “Investor” as defined in the Third Amended and Restated Registration Rights Agreement dated as of the date first above written, by and among Concert Pharmaceuticals, Inc. and the parties named therein (the
“Registration Rights Agreement”), (ii) that each is a party to the Registration Rights Agreement for all purposes and (iii) that each is bound by all terms and conditions of the Registration Rights Agreement. 

EXECUTED this 27th day of May, 2009. 
 THE INVESTORS: 
  

					
		 	  

		 	Name:	 	Peter Kolchinsky
		
		 	  

		 	Name:	 	Caleb Aldrich
		
		 	  

		 	Name:	 	Peter Barton Hutt
	
	RA CAPITAL ASSOCIATES, INC.
		
		 	  

		 	By:	 	Richard H. Aldrich
		 	Title:	 	Managing Director

 

							
		 	To such Investor at:
			
		 	Address:	 	 800 Boylston Street, Suite 1500
		 		 	 Boston, MA 02199

  

							
	TUNG FAMILY INVESTMENT TRUST
			
		 	By:	 	/s/ Roger D. Tung
		 		 	  

		 		 	Name:	 	Roger D. Tung
		 		 	Title:	 	Trustee

  

									
		 		 	 To each such Investor,
 care of the Corporation:

				
		 		 	Address:	 	 99 Hayden Avenue
		 		 		 	  Suite 100

 Lexington, MA

		 		 	Fax:	 	 (781) 860-8923

 [ Investor Signature Page to Concert Pharmaceuticals, Inc. Third Amended and Restated Registration
Rights Agreement ] 

 By executing this page in the space provided, the undersigned hereby agree (i) that
each is an “Investor” as defined in the Third Amended and Restated Registration Rights Agreement dated as of the date first above written, by and among Concert Pharmaceuticals, Inc. and the parties named therein (the
“Registration Rights Agreement”), (ii) that each is a party to the Registration Rights Agreement for all purposes and (iii) that each is bound by all terms and conditions of the Registration Rights Agreement. 

EXECUTED this      day of             , 2009. 

THE INVESTORS: 
  

									
	ALEXANDRIA EQUITIES, LLC
		
	By:	 	Alexandria Real Estate Equities, Inc.
	Its:	 	Managing Member
			
		 	By:	 	  

		 		 	Name:	 	Jennifer J. Pappas
		 		 	Title:	 	Senior Vice President and Assistant Secretary
		
		 	To such Investor at:
			
		 	Address:	 	385 E. Colorado Road
		 		 	 Suite 299

Pasadena, CA 91101

		 		 	Attn:	 	Amanda Cashin,
		 		 		 	Executive Director of Life Sciences
		 	Fax:	 	(626) 578-0770

 [ Investor Signature Page to Concert Pharmaceuticals, Inc. Third Amended and Restated Registration
Rights Agreement ] 

 FIRST AMENDMENT TO 

THIRD AMENDED AND RESTATED REGISTRATION RIGHTS
AGREEMENT 
 December 22, 2011 
 This First Amendment (this “Amendment”) to the Third Amended and Restated Registration Rights Agreement (the “RRA”), dated as of June 1, 2009, by and among Concert
Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and the Investors named therein, is made and entered as of the date first written above. Capitalized terms used and not otherwise defined herein shall have the respective
meanings ascribed to them in the RRA. 
 WHEREAS, the undersigned stockholders of the Company (the “Holders”)
are holders of at least 60% in voting power of the currently outstanding Registrable Shares held by Investors, and, consequently, pursuant to Section 14 of the RRA, may consent to the grant by the Company of further rights with respect to the
Company’s registration of its securities under the Securities Act of 1933, as amended (the “Securities Act”), similar to those currently existing under the RRA; 

WHEREAS, the Holders are holders of at least 60% of the Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock and
Common Stock issued upon conversion of Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock (taken together as a single class on an as-converted to Common Stock basis) in voting power, and, consequently, pursuant to
Section 21(b) of the RRA, may, with the consent of the Company, which is indicated by the signature of its authorized signatory below, consent to an amendment of the RRA on behalf of all parties thereto; 

WHEREAS, in connection with a loan and security agreement (the “Loan and Security Agreement”) to be entered into by and
between the Company and Hercules Technology Growth Capital, Inc., a Maryland corporation (the “Lender”), the Company will issue a warrant to the Lender (the “Warrant”) to purchase shares of the Series C Preferred
Stock; and 
 WHEREAS, to induce the Lender to enter into the Loan and Security Agreement, the undersigned desire to amend the
RRA to provide the shares issuable under the Warrant with rights with respect to registration by the Company of such shares under the Securities Act; 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

1. Amendment to the RRA. 
 a. The definition of “Registrable Shares” in Section 1(f) of the RRA is hereby deleted in its entirety and replaced with the following definition: 

“The term “Registrable Shares” means (1) the Common Stock issued or issuable upon conversion of the Preferred
Stock held by any Investor (other than Hercules and any Hercules Warrant Transferee, each as defined below, the Registable Shares of which shall be determined in accordance with clause (3) below), (2) any Common Stock purchased by an
Investor (or its permitted transferees) pursuant to 

 
Section 3 of the Third Amended and Restated Investor Rights Agreement, dated as of June 1, 2009, by and among the Corporation and certain of the Investors (or Common Stock issuable with
respect to other securities so purchased), (3) any Common Stock issued or issuable upon conversion of any Preferred Stock issued to (i) Hercules Technology Growth Capital, Inc., a Maryland corporation (“Hercules”), upon
exercise of its warrant to purchase shares of Series C Preferred Stock dated as of December 22, 2011 and any other warrant issued to Hercules in conjunction with a future loan advance by Hercules to the Corporation pursuant to the terms of the
Loan and Security Agreement, dated as of December 22, 2011, by and between Hercules and the Corporation (such warrants, collectively, the “Hercules Warrants”) or (ii) any holder of a Hercules Warrant if other than Hercules
(a “Hercules Warrant Transferee”) at any time of exercise thereof by such Hercules Warrant Transferee, provided that the transfer of such Hercules Warrant to such Hercules Warrant Transferee satisfied the requirements of clauses
(a) through (c) of Section 15 of this Agreement, mutatis mutandis, and (4) any Common Stock issued as a dividend or other distribution with respect to, or in exchange or in replacement of, such Preferred Stock or
Common Stock; provided that any Registrable Shares shall cease to be Registrable Shares if transferred by an Investor other than in compliance with the provisions of Section 15 of this Agreement.” 

b. The following definition is hereby inserted as Section 1(j) of the RRA: 

“(j) The term “Demand Rights Holder” means any Holder other than Hercules or a Hercules Warrant Transferee.”

 c. Section 2 of the RRA is hereby deleted in its entirety and replaced with the following: 

“Request for Registration. If at any time after the earlier to occur of (i) the fourth anniversary of the date of the
Original Agreement and (ii) the date six months after the closing of the first public offering of the Corporation’s securities, the Corporation shall receive a written request (specifying that it is being made pursuant to this
Section 2) from one or more Demand Rights Holders that hold, in the aggregate, at least one-third of the then outstanding Registrable Shares held by Demand Rights Holders, that the Corporation file a registration statement under the Securities
Act, or a similar document pursuant to any other statute then in effect corresponding to the Securities Act, covering the registration of at least the lesser of (a) at least one-third of the then outstanding Registrable Shares held by Demand
Rights Holders or (b) Registrable Shares held by Demand Rights Holders the expected price to the public of which equals or exceeds $5,000,000 (based on the market price or fair value on the date of such request), then the Corporation shall
promptly notify all other Holders of such request and shall use its best efforts to cause all Registrable Shares that Holders have requested be registered to be registered under the Securities Act on Form S-1 or any other available form the use of
which is approved by Demand Rights Holders holding a majority of the Registrable Shares held by Demand Rights Holders that are to be included in such registration. 

 Notwithstanding the foregoing, (i) the Corporation shall not be obligated to effect a
registration pursuant to this Section 2 during the period starting with the date sixty (60) days prior to the Corporation’s estimated date of filing of, and ending on a date six (6) months following the effective date of, a
registration statement pertaining to an underwritten public offering of securities for the account of the Corporation, provided that the Corporation is actively employing in good faith its best efforts to cause such registration statement to become
effective and that the Corporation’s estimate of the date of filing such registration statement is made in good faith; (ii) the Corporation shall not be obligated to effect more than two registrations pursuant to this Section 2; and
(iii) if the Corporation shall furnish to the Demand Rights Holders a certificate signed by the President of the Corporation stating that in the good faith judgment of the Board of Directors it would be seriously detrimental to the Corporation
or its stockholders for a registration statement to be filed in the near future, then the Corporation’s obligation to use its best efforts to file a registration statement shall be deferred for a period not to exceed ninety (90) days;
provided, however, that the Corporation shall not be permitted to so defer its obligation more than once in any 12-month period.” 
 d. Section 6 of the RRA is hereby deleted in its entirety and replaced with the following: 
 “Expenses of Demand Registration. All expenses incurred in connection with any registration pursuant to Section 2 or Section 11 (excluding underwriters’ discounts and
commissions), including, without limitation, all registration and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Corporation, and the reasonable fees and disbursements of one special counsel for the
selling Holders collectively, shall be borne by the Corporation whether or not the registration statement to which such registration expenses relate becomes effective; provided, however, that the Corporation shall not be required to pay for
any expenses of any registration proceeding begun pursuant to Section 2 if the registration request is subsequently withdrawn at the request of the Demand Rights Holders holding a majority of the Registrable Shares held by the Demand Rights
Holders to be registered (in which case all participating Holders shall bear such expenses pro rata based upon the number of Registrable Shares that were to be included in the withdrawn registration), unless the Demand Rights Holders holding a
majority of the Registrable Shares held by Demand Rights Holders agree to forfeit their right to one demand registration pursuant to Section 2; provided further, however, that if at the time of such withdrawal, the Demand Rights Holders
have learned of a material adverse change in the condition, business, or prospects of the Corporation from that known to the Demand Rights Holders at the time of their request and have withdrawn the request with reasonable promptness after learning
of such information, then the Holders shall not be required to pay any of such expenses and shall retain their rights pursuant to Section 2.” 

 2. Remaining Provisions of the RRA. Except as provided herein, each of the other
provisions of the RRA shall remain in full force and effect. 
 3. Entire Agreement. The RRA, as supplemented and
modified by this Amendment, together with the any other writings referred to in the RRA or delivered pursuant thereto which form a part thereof, contain the entire agreement among the parties with respect to the subject matter thereof and amend and
supersede all prior and contemporaneous arrangements or understandings with respect thereto. 
 4. References. Upon the
effectiveness of this Amendment, on and after the date hereof, each reference in the RRA to “this Agreement,” “hereunder,” “hereof,” “herein” or words of like import shall mean and be a reference to the RRA,
as amended hereby. 
 5. Governing Law. This Amendment shall be governed by, and construed and enforced in accordance
with, the substantive laws of the Commonwealth of Massachusetts, without regard to its principles of conflicts of laws. 
 6.
Counterparts. This Amendment may be executed in any number of counterparts, each such counterpart shall be deemed to be an original instrument, and all such counterparts together shall constitute but one agreement. Any such counterpart may
contain one or more signature pages. This Amendment may be executed by facsimile signature pages. 
 [Signature Pages Follow]

 IN WITNESS WHEREOF, the undersigned have executed this First Amendment to Third Amended and
Restated Registration Rights Agreement as of the date first written above. 
  

			
	THE COMPANY:
	
	CONCERT PHARMACEUTICALS, INC.
		
	By:	 	/s/ Roger D. Tung
		 	  

	Name:	 	Roger D. Tung
	Title:	 	Chief Executive Officer

 By executing this page in the space provided, the undersigned hereby agrees (i) that it
is an “Investor” as defined in the Third Amended and Restated Registration Rights Agreement dated as of June 1, 2009, by and among Concert Pharmaceuticals, Inc. and the parties named therein, as amended by this First Amendment
to Third Amended and Restated Registration Rights Agreement (the “Registration Rights Agreement”), (ii) that it is a party to the Registration Rights Agreement for all purposes and (ii) that it is bound by all terms and
conditions of the Registration Rights Agreement. 
  

									
	INVESTORS:
	
	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.,
		 	a Maryland corporation
					
		 		 	By:	 		 	 /s/ K. Nicholas Martitsch

		 		 	Name:	 		 	 K. Nicholas Martitsch

		 		 	Title:	 		 	 Associate General Counsel

  

	
	With notice to such Investor at:
	
	HERCULES TECHNOLOGY GROWTH
	CAPITAL INC.
	Legal Department
	Attention: Chief Legal Officer and Janice Bourque
	400 Hamilton Avenue, Suite 310
	Palo Alto, CA 94301
	Facsimile: 650-473-9194
	Telephone: 650-289-3060

 IN WITNESS WHEREOF, the undersigned have executed this First Amendment to Third Amended and
Restated Registration Rights Agreement as of the date first written above. 
  

					
	INVESTORS:
	
	GLAXO GROUP LIMITED
		
	By:	 	/s/ Paul Williamson
		 	  

		 	Name:	 	Paul Williamson
		 	Title:	 	Authorised Signatory For and on behalf of Edinburgh Pharmaceutical Industries Limited Corporate Director

 [2011 Hercules Debt Financing - RRA Amendment] 

 IN WITNESS WHEREOF, the undersigned have executed this First Amendment to Third Amended and
Restated Registration Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	FIDELITY MT. VERNON STREET TRUST:
	FIDELITY GROWTH COMPANY FUND
		
	By:	 	/s/ Jeffrey Christian
		 	  

		 	Name:  Jeffrey Christian
		 	Title:    Deputy Treasurer

  

							
		 	To such Investor at:
			
		 	Address:	 	82 Devonshire Street, V13H
		 		 	Boston, MA 02109
		 		 	Attn:	 	Andrew J. Boyd,
		 		 		 	Associate General Counsel
		 	Fax:	 	(617) 392-1605

 [2011 Hercules Debt Financing - RRA Amendment] 

 IN WITNESS WHEREOF, the undersigned have executed this First Amendment to Third Amended and
Restated Registration Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	WESTFIELD LIFE SCIENCES FUND LP
		
	By:	 	  

		 	Name:  William A. Muggia
		 	Title:    Director

  

			
	WESTFIELD LIFE SCIENCES FUND II LP
		
	By:	 	  

		 	Name:  William A. Muggia
		 	Title:    Director

  

							
		 	To each such Investor at:
		 	Address:	 	Westfield Capital Management
		 		 	One Financial Center, 24th Floor
		 		 	Boston, MA 02111
		 		 	Attn:	 	Eric D. Changelian,
		 		 		 	Manager of Fund Operations
		 	Fax:  (617) 867-2801

 [2011 Hercules Debt Financing - RRA Amendment] 

 IN WITNESS WHEREOF, the undersigned have executed this First Amendment to Third Amended and
Restated Registration Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	ADAGE CAPITAL PARTNERSHIP
		
	By:	 	/s/ Dan Lehan
		 	  

		 	Name:  Dan Lehan
		 	Title:    Chief Operating Officer

  

					
		 	To such Investor at:
		 	Address:	 	200 Clarendon St., 52nd Floor
		 		 	Boston, MA 02116
		 	Fax:	 	(617) 867-2801

 [2011 Hercules Debt Financing - RRA Amendment] 

 IN WITNESS WHEREOF, the undersigned have executed this First Amendment to Third Amended and
Restated Registration Rights Agreement as of the date first written above. 
  

									
	INVESTORS:	 		 		 	
			
	 MEDIPHASE VENTURE PARTNERS II
 LIMITED PARTNERSHIP
	 		 	 MEDIPHASE VENTURE PARTNERS
 (DP & UP) LIMITED PARTNERSHIP

					
	By:	 	Mediphase II LLC	 		 	By:	 	Mediphase (DP&UP) LLC
	Its:	 	General Partner	 		 	Its:	 	General Partner
					
	By:	 	  
	 		 	By:	 	  

		 	Name:  Paul A. Howard	 		 		 	Name:  Paul A. Howard
		 	Title:    Manager	 		 		 	Title:    Manager

  

													
	MEDIPHASE VENTURE PARTNERS II	 		 		 	To each such Investor at:
	(ANNEX FUND) LIMITED	 		 		 		 		 	
	PARTNERSHIP	 		 		 		 	 Address:
	 	Mediphase Venture Partners
		 		 		 		 		 		 	3 Newton Executive Park
	By:	 	Mediphase II (Annex Fund) LLC	 		 		 		 		 	2223 Washington Street
	Its:	 	General Partner	 		 		 		 		 	Suite 104
		 		 		 		 		 		 	Newton, MA 02462
		 		 		 		 		 		 	Attn: Amanda Cobb,
	By:	 	  
	 		 		 		 		 	          Operations Manager
		 	Name: Paul A. Howard	 		 		 		 	Fax:	 	(617) 332-8463
		 	Title: Manager	 		 		 		 		 	

 [2011 Hercules Debt Financing - RRA Amendment] 

 IN WITNESS WHEREOF, the undersigned have executed this First Amendment to Third Amended and
Restated Registration Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	S.R. ONE, LIMITED
		
	By:	 	/s/ Brian M. Gallagher, Jr., Phd
		 	  

		 	Name:  Brian M. Gallagher, Jr., Phd
		 	Title:    Vice President & Partner

  

					
		 	To such Investor at:
		 	Address:	 	161 Washington Street
		 		 	Suite 500
		 		 	Eight Tower Bridge
		 		 	Conshohocken, PA 19428
		 		 	Attn: Rajeev Dadoo, Ph.D,
		 	Fax:	 	(610) 567-1039

 [2011 Hercules Debt Financing - RRA Amendment] 

 IN WITNESS WHEREOF, the undersigned have executed this First Amendment to Third Amended and
Restated Registration Rights Agreement as of the date first written above. 
  

									
	INVESTORS:	 		 		 	
			
	THREE ARCH PARTNERS IV, L.P.	 		 	THREE ARCH PARTNERS III, L.P.
				
	By: Three Arch Management IV, L.L.C.	 		 		 	By: Three Arch Management III, L.L.C.
	Its: General Partner	 		 		 	Its: General Partner
					
	By:	 	/s/ Wilfred Jaeger	 		 	By:	 	/s/ Wilfred Jaeger
		 	  
	 		 		 	  

	Name:	 	Wilfred Jaeger	 		 		 	Name:  Wilfred Jaeger
	Title:	 	Managing Member	 		 		 	Title:    Managing Member
				
	THREE ARCH ASSOCIATES IV, L.P.	 		 		 	THREE ARCH ASSOCIATES III, L.P.
				
	By: Three Arch Management IV, L.L.C.	 		 		 	By: Three Arch Management III, L.L.C.
	Its: General Partner	 		 		 	Its: General Partner
					
	By:	 	/s/ Wilfred Jaeger	 		 	By:	 	/s/ Wilfred Jaeger
		 	  
	 		 		 	  

	Name:	 	Wilfred Jaeger	 		 		 	Name:  Wilfred Jaeger
	Title:	 	Managing Member	 		 		 	Title:    Managing Member
					
		 		 		 		 	To each such Investor at:

 

			
	Address:	 	3200 Alpine Road
		 	Portola Valley, CA 94028
		 	Attn: Steve Bonelli,
		 	  Chief Financial Officer
	Fax:	 	(650) 529-8039

 [2011 Hercules Debt Financing - RRA Amendment] 

 IN WITNESS WHEREOF, the undersigned have executed this First Amendment to Third Amended and
Restated Registration Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	GREYLOCK XII LIMITED PARTNERSHIP
		
	By:	 	Greylock XII GP LLC, its General Partner
		
	By:	 	  

		 	Name:  Donald A. Sullivan
		 	Title:    Administrative Partner
	
	GREYLOCK XII-A LIMITED PARTNERSHIP
		
	By:	 	Greylock XII GP LLC, its General Partner
		
	By:	 	  

		 	Name:  Donald A. Sullivan
		 	Title:    Administrative Partner
	
	GREYLOCK XII PRINCIPALS LLC
		
	By:	 	Greylock Management Corporation,
		 	Sole Member
		
	By:	 	  

		 	Name:  Donald A. Sullivan
		 	Title:    Treasurer

  

					
	To each such Investor at:
			
		 	Address:	 	880 Winter Street
		 		 	Waltham, MA 02451
		 		 	 Attn:    Donald A. Sullivan,
     Treasurer

		 	Fax:	 	(781) 622-2326

 [2011 Hercules Debt Financing - RRA Amendment] 

 IN WITNESS WHEREOF, the undersigned have executed this First Amendment to Third Amended and
Restated Registration Rights Agreement as of the date first written above. 
 INVESTORS: 

 

					
	 TVM LIFE SCIENCE VENTURES VI
 GMBH & CO. KG

		
		 	/s/ Mark C. Cipriano
		 	  

		 	By:	 	Mark C. Cipriano
		 	Its:	 	Managing Limited Partner
		
		 	/s/ Alexandra Goll
		 	  

		 	By:	 	Alexandra Goll
		 	Its:	 	Managing Limited Partner
	
	TVM LIFE SCIENCE VENTURES VI LP
		
		 	/s/ Mark C. Cipriano
		 	  

		 	By:	 	Mark C. Cipriano
		 	Its:	 	Authorized Officer
		
		 	/s/ Alexandra Goll
		 	  

		 	By:	 	Alexandra Goll
		 	Its:	 	Authorized Officer

  

					
		 	To each such Investor at:
			
		 	Address:	 	 470 Atlantic Ave
 4th
Floor
 Boston MA. 02210
 Attn: Mark
Cipriano

		 	Fax:	 	617-273-8001

 [2011 Hercules Debt Financing - RRA Amendment] 

 IN WITNESS WHEREOF, the undersigned have executed this First Amendment to Third Amended and
Restated Registration Rights Agreement as of the date first written above. 
 INVESTORS: 

 

			
	 SKYLINE VENTURE PARTNERS
 QUALIFIED PURCHASER FUND IV, L.P.

		
	By:	 	Skyline Venture Management IV, LLC
	Its:	 	General Partner
		
	By:	 	/s/ John Freund
		 	  

		 	Name: John Freund
		 	Title:   Managing Directory

  

					
	To such Investor at:
			
		 	Address:	 	c/o Skyline Ventures
		 		 	525 University Avenue
		 		 	  Suite 520
		 		 	Palo Alto, CA 94301
		 		 	Attn: Kerry Kenny
		 	Fax:	 	(650) 329-1090

 [2011 Hercules Debt Financing - RRA Amendment] 

 IN WITNESS WHEREOF, the undersigned have executed this First Amendment to Third Amended and
Restated Registration Rights Agreement as of the date first written above. 
 INVESTORS: 

 

					
	QVT FUND LP
		
	By:	 	QVT Associates GP LLC
	Its:	 	General Partner
		
	By:	 	  

		 	Name:	 	
		 	Title:	 	Managing Member
		
	By:	 	  

		 	Name:	 	  

		 	Title:	 	  

  

					
		 	To such Investor at:
			
		 	Address:	 	c/o QVT Financial LP
		 		 	1177 Avenue of the Americas
		 		 	9th Floor
		 		 	New York, NY 10036
		 		 	Attn: Keith Manchester
		 	Fax:	 	(212) 705-8820
		
		 	Note: Registered Address is:
			
		 	Address:	 	c/o Walkers SPV
		 		 	Walker House
		 		 	P.O. Box 908GT, Mary Street
		 		 	George Town, Grand Cayman
		 		 	Cayman Islands

  
 [2011
Hercules Debt Financing - RRA Amendment] 

 IN WITNESS WHEREOF, the undersigned have executed this First Amendment to Third Amended and
Restated Registration Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	FLAGSHIP VENTURES FUND 2004, L.P.
		
	By:	 	Flagship Ventures General Partner, LLC
		 	its General Partner
		
	By:	 	/s/ Noubar Afeyan
		 	  

		 	Name:  Noubar Afeyan
		 	Title:

  

					
		 	To such Investor at:
			
		 	Address:	 	One Memorial Drive
		 		 	7th Floor
		 		 	Cambridge, MA 02142
		 		 	Attn: Douglas G. Cole, M.D.
		 	Fax:	 	(617) 868-1115

  
 [2011
Hercules Debt Financing - RRA Amendment] 

 IN WITNESS WHEREOF, the undersigned have executed this First Amendment to Third Amended and
Restated Registration Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	BROOKSIDE CAPITAL PARTNERS FUND, LP
		
	By:	 	/s/ Adam M Koppel
		 	  

		 	Name:  Adam M Koppel
		 	Title:    Managing Director

  

					
		 	To such Investor at:
			
		 	Address:	 	c/o Bain Capital
		 		 	111 Huntington Avenue
		 		 	Boston, MA 02199
		 		 	Attn: Marlene Wojcik,
		 		 	      Chief Financial Officer
		 	Fax:	 	(617) 516-2910

  
 [2011
Hercules Debt Financing - RRA Amendment] 

 IN WITNESS WHEREOF, the undersigned have executed this First Amendment to Third Amended and
Restated Registration Rights Agreement as of the date first written above. 
  

			
	INVESTORS:
	
	NEW LEAF VENTURES I, L.P.
		
	By:	 	New Leaf Venture Management I, L.P.
	Its:	 	General Partner
		
	By:	 	New Leaf Venture Management I, L.L.C.
	Its:	 	General Partner
		
	By:	 	/s/ Craig L. Slutzkin
		 	  

		 	Name:  Craig L. Slutzkin,
		 	Title:    Chief Financial Officer

  

					
		 	To such Investor at:
			
		 	Address:	 	2500 Sand Hill Road
		 		 	Suite 203
		 		 	Menlo Park, CA 94025
		 		 	Attn: Craig L. Slutzkin,
		 		 	      Chief Financial Officer
		 	Fax:	 	(650) 234-2704

  
 [2011
Hercules Debt Financing - RRA Amendment] 

 IN WITNESS WHEREOF, the undersigned have executed this First Amendment to Third Amended and
Restated Registration Rights Agreement as of the date first written above. 
  

					
	INVESTORS:
		
		 	  

		 	Name:	 	Peter Kolchinsky
		
		 	  

		 	Name:	 	Caleb Aldrich
		
		 	  

		 	Name:	 	Peter Barton Hutt
		
		 	RA CAPITAL ASSOCIATES, INC.
		
		 	  

		 	By:	 	Richard H. Aldrich
		 	Title:	 	Managing Director

  

					
		 	To such Investor at:
			
		 	Address:	 	800 Boylston Street, Suite 1500
		 		 	Boston, MA 02199

  

					
		 	TUNG FAMILY INVESTMENT TRUST
			
		 	By:	 	  

		 		 	Name:  Roger D. Tung
		 		 	Title:    Trustee

  

							
		 		 	To each such Investor,
		 		 	care of the Corporation:
				
		 		 	Address:	 	99 Hayden Avenue
		 		 		 	Suite 100
		 		 	          Lexington, MA
		 		 	Fax:	 	(781) 860-8923

  
 [2011
Hercules Debt Financing - RRA Amendment] 

 IN WITNESS WHEREOF, the undersigned have executed this First Amendment to Third Amended and
Restated Registration Rights Agreement as of the date first written above. 
  

							
	 INVESTORS:
  

ALEXANDRIA EQUITIES, LLC

	By:	 	Alexandria Real Estate Equities, Inc.
	Its:	 	Managing Member
			
		 	By:	 	  

		 		 	Name:	 	Jennifer J. Pappas
		 		 	Title:	 	Senior Vice President and Assistant Secretary

  

					
		 	To such Investor at:
			
		 	Address:	 	385 E. Colorado Road
		 		 	Suite 299
		 		 	Pasadena, CA 91101
		 		 	Attn: Amanda Cashin,
		 		 	          Executive Director of Life           Sciences
		 	Fax:	 	(626) 578-0770

  
 [2011
Hercules Debt Financing - RRA Amendment]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]